1
|
Wille K, Deventer E, Sadjadian P, Becker T, Kolatzki V, Hünerbein K, Meixner R, Jiménez-Muñoz M, Fuchs C, Griesshammer M. Arterial and Venous Thromboembolic Complications in 832 Patients with BCR-ABL-Negative Myeloproliferative Neoplasms. Hamostaseologie 2023. [PMID: 37813367 DOI: 10.1055/a-2159-8767] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/11/2023] Open
Abstract
Arterial (ATE) and venous (VTE) thromboembolic complications are common causes of morbidity and mortality in BCR-ABL-negative myeloproliferative neoplasms (MPNs). However, there are few studies that include all MPN subtypes and focus on both MPN-associated ATE and VTE. In our single-center retrospective study of 832 MPN patients, a total of 180 first thromboembolic events occurred during a median follow-up of 6.6 years (range: 0-37.6 years), of which 105 were VTE and 75 were ATE. The probability of a vascular event at the end of the follow-up period was 36.2%, and the incidence rate for all first ATE/VTE was 2.43% patient/year. The most frequent VTE localizations were deep vein thrombosis with or without pulmonary embolism (incidence rate: 0.59% patient/year), while strokes were the most frequent ATE with an incidence rate of 0.32% patient/year. When comparing the group of patients with ATE/VTE (n = 180) and the group without such an event (n = 652) using multivariate Cox regression analyses, patients with polycythemia vera (hazard ratio [HR]: 1.660; [95% confidence interval [CI] 1.206, 2.286]) had a significantly higher risk of a thromboembolic event than the other MPN subtypes. In contrast, patients with a CALR mutation had a significantly lower risk of thromboembolism compared with JAK2-mutated MPN patients (HR: 0.346; [95% CI: 0.172, 0.699]). In summary, a high incidence of MPN-associated VTE and ATE was observed in our retrospective study. While PV patients or generally JAK2-mutated MPN patients had a significantly increased risk of such vascular events, this risk was reduced in CALR-mutated MPN patients.
Collapse
Affiliation(s)
- Kai Wille
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Bochum, Germany
| | - Eva Deventer
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Bochum, Germany
| | - Parvis Sadjadian
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Bochum, Germany
| | - Tatjana Becker
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Bochum, Germany
| | - Vera Kolatzki
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Bochum, Germany
| | - Karlo Hünerbein
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Bochum, Germany
| | - Raphael Meixner
- Core Facility Statistical Consulting, Helmholtz Zentrum München, Munich, Germany
| | - Marina Jiménez-Muñoz
- Core Facility Statistical Consulting, Helmholtz Zentrum München, Munich, Germany
| | - Christiane Fuchs
- Core Facility Statistical Consulting, Helmholtz Zentrum München, Munich, Germany
- Faculty of Business Administration and Economics, Bielefeld University, Bielefeld, Germany
| | - Martin Griesshammer
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Bochum, Germany
| |
Collapse
|
2
|
Reinkemeyer C, Khazaei Y, Weigert M, Hannes M, Le Gleut R, Plank M, Winter S, Noreña I, Meier T, Xu L, Rubio-Acero R, Wiegrebe S, Le Thi TG, Fuchs C, Radon K, Paunovic I, Janke C, Wieser A, Küchenhoff H, Hoelscher M, Castelletti N. The Prospective COVID-19 Post-Immunization Serological Cohort in Munich (KoCo-Impf): Risk Factors and Determinants of Immune Response in Healthcare Workers. Viruses 2023; 15:1574. [PMID: 37515259 PMCID: PMC10383736 DOI: 10.3390/v15071574] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2023] [Revised: 07/11/2023] [Accepted: 07/15/2023] [Indexed: 07/30/2023] Open
Abstract
Antibody studies analyze immune responses to SARS-CoV-2 vaccination and infection, which is crucial for selecting vaccination strategies. In the KoCo-Impf study, conducted between 16 June and 16 December 2021, 6088 participants aged 18 and above from Munich were recruited to monitor antibodies, particularly in healthcare workers (HCWs) at higher risk of infection. Roche Elecsys® Anti-SARS-CoV-2 assays on dried blood spots were used to detect prior infections (anti-Nucleocapsid antibodies) and to indicate combinations of vaccinations/infections (anti-Spike antibodies). The anti-Spike seroprevalence was 94.7%, whereas, for anti-Nucleocapsid, it was only 6.9%. HCW status and contact with SARS-CoV-2-positive individuals were identified as infection risk factors, while vaccination and current smoking were associated with reduced risk. Older age correlated with higher anti-Nucleocapsid antibody levels, while vaccination and current smoking decreased the response. Vaccination alone or combined with infection led to higher anti-Spike antibody levels. Increasing time since the second vaccination, advancing age, and current smoking reduced the anti-Spike response. The cumulative number of cases in Munich affected the anti-Spike response over time but had no impact on anti-Nucleocapsid antibody development/seropositivity. Due to the significantly higher infection risk faced by HCWs and the limited number of significant risk factors, it is suggested that all HCWs require protection regardless of individual traits.
Collapse
Affiliation(s)
- Christina Reinkemeyer
- Division of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany
| | - Yeganeh Khazaei
- Statistical Consulting Unit StaBLab, Department of Statistics, LMU Munich, Ludwigstraße 33, 80539 Munich, Germany
| | - Maximilian Weigert
- Statistical Consulting Unit StaBLab, Department of Statistics, LMU Munich, Ludwigstraße 33, 80539 Munich, Germany
- Munich Center for Machine Learning (MCML), 80539 Munich, Germany
| | - Marlene Hannes
- Division of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany
| | - Ronan Le Gleut
- Institute of Computational Biology, Helmholtz Munich, 85764 Neuherberg, Germany
- Core Facility Statistical Consulting, Helmholtz Munich, 85764 Neuherberg, Germany
| | - Michael Plank
- Division of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany
| | - Simon Winter
- Division of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany
| | - Ivan Noreña
- Division of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany
| | - Theresa Meier
- Statistical Consulting Unit StaBLab, Department of Statistics, LMU Munich, Ludwigstraße 33, 80539 Munich, Germany
| | - Lisa Xu
- Statistical Consulting Unit StaBLab, Department of Statistics, LMU Munich, Ludwigstraße 33, 80539 Munich, Germany
| | - Raquel Rubio-Acero
- Division of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany
| | - Simon Wiegrebe
- Statistical Consulting Unit StaBLab, Department of Statistics, LMU Munich, Ludwigstraße 33, 80539 Munich, Germany
- Department of Genetic Epidemiology, University of Regensburg, 93053 Regensburg, Germany
| | - Thu Giang Le Thi
- Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Lindwurmstrasse 4, 80337 Munich, Germany
| | - Christiane Fuchs
- Institute of Computational Biology, Helmholtz Munich, 85764 Neuherberg, Germany
- Core Facility Statistical Consulting, Helmholtz Munich, 85764 Neuherberg, Germany
- Faculty of Business Administration and Economics, Bielefeld University, 33615 Bielefeld, Germany
- Center for Mathematics, Technische Universität München, 85748 Garching, Germany
| | - Katja Radon
- Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, 80336 Munich, Germany
- Center for International Health (CIH), University Hospital, LMU Munich, 80336 Munich, Germany
- Comprehensive Pneumology Center (CPC) Munich, German Center for Lung Research (DZL), 89337 Munich, Germany
| | - Ivana Paunovic
- Division of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany
| | - Christian Janke
- Division of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany
| | - Andreas Wieser
- Division of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany
- German Center for Infection Research (DZIF), Partner Site Munich, 80802 Munich, Germany
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection and Pandemic Research, 80799 Munich, Germany
- Max von Pettenkofer Institute, Faculty of Medicine, LMU Munich, 80336 Munich, Germany
| | - Helmut Küchenhoff
- Statistical Consulting Unit StaBLab, Department of Statistics, LMU Munich, Ludwigstraße 33, 80539 Munich, Germany
| | - Michael Hoelscher
- Division of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany
- Center for International Health (CIH), University Hospital, LMU Munich, 80336 Munich, Germany
- German Center for Infection Research (DZIF), Partner Site Munich, 80802 Munich, Germany
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection and Pandemic Research, 80799 Munich, Germany
| | - Noemi Castelletti
- Division of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection and Pandemic Research, 80799 Munich, Germany
- Institute of Radiation Medicine, Helmholtz Zentrum München, 85764 Neuherberg, Germany
| |
Collapse
|
3
|
Le Gleut R, Plank M, Pütz P, Radon K, Bakuli A, Rubio-Acero R, Paunovic I, Rieß F, Winter S, Reinkemeyer C, Schälte Y, Olbrich L, Hannes M, Kroidl I, Noreña I, Janke C, Wieser A, Hoelscher M, Fuchs C, Castelletti N. The representative COVID-19 cohort Munich (KoCo19): from the beginning of the pandemic to the Delta virus variant. BMC Infect Dis 2023; 23:466. [PMID: 37442952 DOI: 10.1186/s12879-023-08435-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2023] [Accepted: 06/30/2023] [Indexed: 07/15/2023] Open
Abstract
BACKGROUND Population-based serological studies allow to estimate prevalence of SARS-CoV-2 infections despite a substantial number of mild or asymptomatic disease courses. This became even more relevant for decision making after vaccination started. The KoCo19 cohort tracks the pandemic progress in the Munich general population for over two years, setting it apart in Europe. METHODS Recruitment occurred during the initial pandemic wave, including 5313 participants above 13 years from private households in Munich. Four follow-ups were held at crucial times of the pandemic, with response rates of at least 70%. Participants filled questionnaires on socio-demographics and potential risk factors of infection. From Follow-up 2, information on SARS-CoV-2 vaccination was added. SARS-CoV-2 antibody status was measured using the Roche Elecsys® Anti-SARS-CoV-2 anti-N assay (indicating previous infection) and the Roche Elecsys® Anti-SARS-CoV-2 anti-S assay (indicating previous infection and/or vaccination). This allowed us to distinguish between sources of acquired antibodies. RESULTS The SARS-CoV-2 estimated cumulative sero-prevalence increased from 1.6% (1.1-2.1%) in May 2020 to 14.5% (12.7-16.2%) in November 2021. Underreporting with respect to official numbers fluctuated with testing policies and capacities, becoming a factor of more than two during the second half of 2021. Simultaneously, the vaccination campaign against the SARS-CoV-2 virus increased the percentage of the Munich population having antibodies, with 86.8% (85.5-87.9%) having developed anti-S and/or anti-N in November 2021. Incidence rates for infections after (BTI) and without previous vaccination (INS) differed (ratio INS/BTI of 2.1, 0.7-3.6). However, the prevalence of infections was higher in the non-vaccinated population than in the vaccinated one. Considering the whole follow-up time, being born outside Germany, working in a high-risk job and living area per inhabitant were identified as risk factors for infection, while other socio-demographic and health-related variables were not. Although we obtained significant within-household clustering of SARS-CoV-2 cases, no further geospatial clustering was found. CONCLUSIONS Vaccination increased the coverage of the Munich population presenting SARS-CoV-2 antibodies, but breakthrough infections contribute to community spread. As underreporting stays relevant over time, infections can go undetected, so non-pharmaceutical measures are crucial, particularly for highly contagious strains like Omicron.
Collapse
Affiliation(s)
- Ronan Le Gleut
- Institute of Computational Biology, Helmholtz Munich, German Research Centre for Environmental Health, 85764, Neuherberg, Germany
- Core Facility Statistical Consulting, Helmholtz Munich, German Research Centre for Environmental Health, 85764, Neuherberg, Germany
| | - Michael Plank
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
| | - Peter Pütz
- Robert Koch Institute, Nordufer 20, 13353, Berlin, Germany
| | - Katja Radon
- Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, 80336, Munich, Germany
- Centre for International Health (CIH), University Hospital, LMU Munich, 80336, Munich, Germany
- Comprehensive Pneumology Centre (CPC) Munich, German Centre for Lung Research (DZL), 89337, Munich, Germany
| | - Abhishek Bakuli
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
| | - Raquel Rubio-Acero
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
| | - Ivana Paunovic
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
| | - Friedrich Rieß
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
| | - Simon Winter
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
| | - Christina Reinkemeyer
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
| | - Yannik Schälte
- Institute of Computational Biology, Helmholtz Munich, German Research Centre for Environmental Health, 85764, Neuherberg, Germany
- Centre for Mathematics, Technische Universität München, 85748, Garching, Germany
- Life and Medical Sciences Institute, University of Bonn, 53115, Bonn, Germany
| | - Laura Olbrich
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
| | - Marlene Hannes
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
| | - Inge Kroidl
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
| | - Ivan Noreña
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
| | - Christian Janke
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
| | - Andreas Wieser
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
- German Centre for Infection Research (DZIF), Partner Site, Munich, Germany
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection and Pandemic Research, 80799, Munich, Germany
- Max Von Pettenkofer Institute, Faculty of Medicine, LMU Munich, 80336, Munich, Germany
| | - Michael Hoelscher
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
- Centre for International Health (CIH), University Hospital, LMU Munich, 80336, Munich, Germany
- German Centre for Infection Research (DZIF), Partner Site, Munich, Germany
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection and Pandemic Research, 80799, Munich, Germany
| | - Christiane Fuchs
- Institute of Computational Biology, Helmholtz Munich, German Research Centre for Environmental Health, 85764, Neuherberg, Germany
- Core Facility Statistical Consulting, Helmholtz Munich, German Research Centre for Environmental Health, 85764, Neuherberg, Germany
- Centre for Mathematics, Technische Universität München, 85748, Garching, Germany
- Faculty of Business Administration and Economics, Bielefeld University, 33615, Bielefeld, Germany
| | - Noemi Castelletti
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany.
- Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection and Pandemic Research, 80799, Munich, Germany.
- Institute of Radiation Medicine, Helmholtz Munich, German Research Centre for Environmental Health, 85764, Neuherberg, Germany.
| |
Collapse
|
4
|
Wille K, Brouka M, Bernhardt J, Rüfer A, Niculescu-Mizil E, Gotic M, Isfort S, Koschmieder S, Barbui T, Sadjadian P, Becker T, Kolatzki V, Meixner R, Marchi H, Fuchs C, Stegelmann F, Döhner K, Kiladjian JJ, Griesshammer M. Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET. Hemasphere 2023; 7:e882. [PMID: 37153877 PMCID: PMC10155895 DOI: 10.1097/hs9.0000000000000882] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2022] [Accepted: 03/30/2023] [Indexed: 05/10/2023] Open
Affiliation(s)
- Kai Wille
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Germany
| | - Maja Brouka
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Germany
| | - Johannes Bernhardt
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Germany
| | - Axel Rüfer
- Luzerner Kantonsspital, Division of Hematology, Luzern, Switzerland
| | | | - Mirjana Gotic
- Clinic for Hematology Clinical Center of Serbia, Medical Faculty University of Belgrade, Serbia
| | - Susanne Isfort
- Department of Medicine (Hematology, Oncology, Hemostaseology and SCT), Faculty of Medicine, RWTH Aachen University, Germany
- Center of Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Germany
| | - Steffen Koschmieder
- Department of Medicine (Hematology, Oncology, Hemostaseology and SCT), Faculty of Medicine, RWTH Aachen University, Germany
- Center of Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Germany
| | - Tiziano Barbui
- Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy
| | - Parvis Sadjadian
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Germany
| | - Tatjana Becker
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Germany
| | - Vera Kolatzki
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Germany
| | - Raphael Meixner
- Core Facility Statistical Consulting, Helmholtz Zentrum München, Munich, Germany
| | - Hannah Marchi
- Core Facility Statistical Consulting, Helmholtz Zentrum München, Munich, Germany
- Faculty of Business Administration and Economics, Bielefeld University, Germany
| | - Christiane Fuchs
- Core Facility Statistical Consulting, Helmholtz Zentrum München, Munich, Germany
- Faculty of Business Administration and Economics, Bielefeld University, Germany
| | - Frank Stegelmann
- Department of Internal Medicine III, University Hospital of Ulm, Germany
| | - Konstanze Döhner
- Department of Internal Medicine III, University Hospital of Ulm, Germany
| | - Jean-Jacques Kiladjian
- Université Paris Cité, AP-HP, Hôpital Saint-Louis, Centre d’Investigations Cliniques, Paris, France
| | - Martin Griesshammer
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Germany
| |
Collapse
|
5
|
Gollmann-Tepeköylü C, Graber M, Hirsch J, Mair S, Naschberger A, Pölzl L, Nägele F, Kirchmair E, Degenhart G, Demetz E, Hilbe R, Chen HY, Engert JC, Böhm A, Franz N, Lobenwein D, Lener D, Fuchs C, Weihs A, Töchterle S, Vogel GF, Schweiger V, Eder J, Pietschmann P, Seifert M, Kronenberg F, Coassin S, Blumer M, Hackl H, Meyer D, Feuchtner G, Kirchmair R, Troppmair J, Krane M, Weiss G, Tsimikas S, Thanassoulis G, Grimm M, Rupp B, Huber LA, Zhang SY, Casanova JL, Tancevski I, Holfeld J. Toll-Like Receptor 3 Mediates Aortic Stenosis Through a Conserved Mechanism of Calcification. Circulation 2023; 147:1518-1533. [PMID: 37013819 DOI: 10.1161/circulationaha.122.063481] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 04/05/2023]
Abstract
BACKGROUND Calcific aortic valve disease (CAVD) is characterized by a phenotypic switch of valvular interstitial cells to bone-forming cells. Toll-like receptors (TLRs) are evolutionarily conserved pattern recognition receptors at the interface between innate immunity and tissue repair. Type I interferons (IFNs) are not only crucial for an adequate antiviral response but also implicated in bone formation. We hypothesized that the accumulation of endogenous TLR3 ligands in the valvular leaflets may promote the generation of osteoblast-like cells through enhanced type I IFN signaling. METHODS Human valvular interstitial cells isolated from aortic valves were challenged with mechanical strain or synthetic TLR3 agonists and analyzed for bone formation, gene expression profiles, and IFN signaling pathways. Different inhibitors were used to delineate the engaged signaling pathways. Moreover, we screened a variety of potential lipids and proteoglycans known to accumulate in CAVD lesions as potential TLR3 ligands. Ligand-receptor interactions were characterized by in silico modeling and verified through immunoprecipitation experiments. Biglycan (Bgn), Tlr3, and IFN-α/β receptor alpha chain (Ifnar1)-deficient mice and a specific zebrafish model were used to study the implication of the byglycan (BGN)-TLR3-IFN axis in both CAVD and bone formation in vivo. Two large-scale cohorts (GERA [Genetic Epidemiology Research on Adult Health and Aging], n=55 192 with 3469 aortic stenosis cases; UK Biobank, n=257 231 with 2213 aortic stenosis cases) were examined for genetic variation at genes implicated in BGN-TLR3-IFN signaling associating with CAVD in humans. RESULTS Here, we identify TLR3 as a central molecular regulator of calcification in valvular interstitial cells and unravel BGN as a new endogenous agonist of TLR3. Posttranslational BGN maturation by xylosyltransferase 1 (XYLT1) is required for TLR3 activation. Moreover, BGN induces the transdifferentiation of valvular interstitial cells into bone-forming osteoblasts through the TLR3-dependent induction of type I IFNs. It is intriguing that Bgn-/-, Tlr3-/-, and Ifnar1-/- mice are protected against CAVD and display impaired bone formation. Meta-analysis of 2 large-scale cohorts with >300 000 individuals reveals that genetic variation at loci relevant to the XYLT1-BGN-TLR3-interferon-α/β receptor alpha chain (IFNAR) 1 pathway is associated with CAVD in humans. CONCLUSIONS This study identifies the BGN-TLR3-IFNAR1 axis as an evolutionarily conserved pathway governing calcification of the aortic valve and reveals a potential therapeutic target to prevent CAVD.
Collapse
Affiliation(s)
- Can Gollmann-Tepeköylü
- Department of Cardiac Surgery, Medical University of Innsbruck, Austria. (C.G.-T., M.G, J.H., S.M., L.P., F.N., E.K., N.F., D. Lobenwein, V.S., J.E., M.G., J.H.)
| | - Michael Graber
- Department of Cardiac Surgery, Medical University of Innsbruck, Austria. (C.G.-T., M.G, J.H., S.M., L.P., F.N., E.K., N.F., D. Lobenwein, V.S., J.E., M.G., J.H.)
| | - Jakob Hirsch
- Department of Cardiac Surgery, Medical University of Innsbruck, Austria. (C.G.-T., M.G, J.H., S.M., L.P., F.N., E.K., N.F., D. Lobenwein, V.S., J.E., M.G., J.H.)
| | - Sophia Mair
- Department of Cardiac Surgery, Medical University of Innsbruck, Austria. (C.G.-T., M.G, J.H., S.M., L.P., F.N., E.K., N.F., D. Lobenwein, V.S., J.E., M.G., J.H.)
| | - Andreas Naschberger
- Institute of Genetic Epidemiology, Department of Genetics and Pharmacology, Medical University of Innsbruck, Austria. (A.N., F.K., S.C., B.R.)
- Division of Biological and Environmental Sciences and Engineering, King Abdullah University of Science and Technology, Thuwal4 Saudi Arabia (A.N.)
| | - Leo Pölzl
- Department of Cardiac Surgery, Medical University of Innsbruck, Austria. (C.G.-T., M.G, J.H., S.M., L.P., F.N., E.K., N.F., D. Lobenwein, V.S., J.E., M.G., J.H.)
| | - Felix Nägele
- Department of Cardiac Surgery, Medical University of Innsbruck, Austria. (C.G.-T., M.G, J.H., S.M., L.P., F.N., E.K., N.F., D. Lobenwein, V.S., J.E., M.G., J.H.)
| | - Elke Kirchmair
- Department of Cardiac Surgery, Medical University of Innsbruck, Austria. (C.G.-T., M.G, J.H., S.M., L.P., F.N., E.K., N.F., D. Lobenwein, V.S., J.E., M.G., J.H.)
| | - Gerald Degenhart
- Department of Radiology, Core Facility for Micro-CT, Medical University of Innsbruck, Austria. (G.D., G..F.)
| | - Egon Demetz
- Department of Internal Medicine III, Medical University of Innsbruck, Austria. (E.D., R.H., A.B., D. Lener, M.S., R.K., G.W., I.T.)
| | - Richard Hilbe
- Department of Internal Medicine III, Medical University of Innsbruck, Austria. (E.D., R.H., A.B., D. Lener, M.S., R.K., G.W., I.T.)
| | - Hao-Yu Chen
- Preventive and Genomic Cardiology, McGill University Health Centre Research Institute, Montreal, Quebec, Canada (J.C.E., H.-Y.C., G.T.)
| | - James C Engert
- Preventive and Genomic Cardiology, McGill University Health Centre Research Institute, Montreal, Quebec, Canada (J.C.E., H.-Y.C., G.T.)
| | - Anna Böhm
- Department of Internal Medicine III, Medical University of Innsbruck, Austria. (E.D., R.H., A.B., D. Lener, M.S., R.K., G.W., I.T.)
| | - Nadja Franz
- Department of Cardiac Surgery, Medical University of Innsbruck, Austria. (C.G.-T., M.G, J.H., S.M., L.P., F.N., E.K., N.F., D. Lobenwein, V.S., J.E., M.G., J.H.)
| | - Daniela Lobenwein
- Department of Cardiac Surgery, Medical University of Innsbruck, Austria. (C.G.-T., M.G, J.H., S.M., L.P., F.N., E.K., N.F., D. Lobenwein, V.S., J.E., M.G., J.H.)
| | - Daniela Lener
- Department of Internal Medicine III, Medical University of Innsbruck, Austria. (E.D., R.H., A.B., D. Lener, M.S., R.K., G.W., I.T.)
| | - Christiane Fuchs
- Department Life Science Engineering, University of Applied Sciences Technikum Wien, Vienna, Austria. (C.F., A.W.)
| | - Anna Weihs
- Department Life Science Engineering, University of Applied Sciences Technikum Wien, Vienna, Austria. (C.F., A.W.)
| | - Sonja Töchterle
- Institute of Molecular Biology/CMBI, University of Innsbruck, Austria. (S.T., D.M.)
| | - Georg F Vogel
- Department of Pediatrics/Institute of Cell Biology, Medical University of Innsbruck, Austria. (G.V.F.)
| | - Victor Schweiger
- Department of Cardiac Surgery, Medical University of Innsbruck, Austria. (C.G.-T., M.G, J.H., S.M., L.P., F.N., E.K., N.F., D. Lobenwein, V.S., J.E., M.G., J.H.)
| | - Jonas Eder
- Department of Cardiac Surgery, Medical University of Innsbruck, Austria. (C.G.-T., M.G, J.H., S.M., L.P., F.N., E.K., N.F., D. Lobenwein, V.S., J.E., M.G., J.H.)
| | - Peter Pietschmann
- Division of Cellular and Molecular Pathophysiology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Austria (P.P.)
| | - Markus Seifert
- Department of Internal Medicine III, Medical University of Innsbruck, Austria. (E.D., R.H., A.B., D. Lener, M.S., R.K., G.W., I.T.)
| | - Florian Kronenberg
- Institute of Genetic Epidemiology, Department of Genetics and Pharmacology, Medical University of Innsbruck, Austria. (A.N., F.K., S.C., B.R.)
| | - Stefan Coassin
- Institute of Genetic Epidemiology, Department of Genetics and Pharmacology, Medical University of Innsbruck, Austria. (A.N., F.K., S.C., B.R.)
| | - Michael Blumer
- Institute of Clinical and Functional Anatomy, Innsbruck Medical University, Austria (M.B.)
| | - Hubert Hackl
- Institute of Bioinformatics, Medical University of Innsbruck, Austria. (H.H.)
| | - Dirk Meyer
- Institute of Molecular Biology/CMBI, University of Innsbruck, Austria. (S.T., D.M.)
| | - Gudrun Feuchtner
- Department of Radiology, Core Facility for Micro-CT, Medical University of Innsbruck, Austria. (G.D., G..F.)
| | - Rudolf Kirchmair
- Department of Internal Medicine III, Medical University of Innsbruck, Austria. (E.D., R.H., A.B., D. Lener, M.S., R.K., G.W., I.T.)
| | - Jakob Troppmair
- Daniel Swarovski Research Laboratory, Department of Visceral, Transplant and Thoracic Surgery, University of Innsbruck, Austria. (J.T.)
| | - Markus Krane
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University Munich, Germany (M.K.)
| | - Günther Weiss
- Department of Internal Medicine III, Medical University of Innsbruck, Austria. (E.D., R.H., A.B., D. Lener, M.S., R.K., G.W., I.T.)
| | - Sotirios Tsimikas
- Division of Cardiovascular Diseases, University of California, San Diego, La Jolla (S.T.)
| | - George Thanassoulis
- Preventive and Genomic Cardiology, McGill University Health Centre Research Institute, Montreal, Quebec, Canada (J.C.E., H.-Y.C., G.T.)
| | - Michael Grimm
- Department of Cardiac Surgery, Medical University of Innsbruck, Austria. (C.G.-T., M.G, J.H., S.M., L.P., F.N., E.K., N.F., D. Lobenwein, V.S., J.E., M.G., J.H.)
| | - Bernhard Rupp
- Institute of Genetic Epidemiology, Department of Genetics and Pharmacology, Medical University of Innsbruck, Austria. (A.N., F.K., S.C., B.R.)
| | - Lukas A Huber
- Institute of Cell Biology, Medical University of Innsbruck, Austria. (L.A.H.)
- Austrian Drug Screening Institute, ADSI, Innsbruck (L.A.H.)
| | - Shen-Ying Zhang
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY (S.-Y.Z., J.-L.C.)
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France (S.-Y.Z., J.-L.C.)
- University of Paris, Imagine Institute, France (S.-Y.Z., J.-L.C.)
| | - Jean-Laurent Casanova
- St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY (S.-Y.Z., J.-L.C.)
- Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France (S.-Y.Z., J.-L.C.)
- University of Paris, Imagine Institute, France (S.-Y.Z., J.-L.C.)
- Howard Hughes Medical Institute, New York, NY (J.-L.C.)
| | - Ivan Tancevski
- Department of Internal Medicine III, Medical University of Innsbruck, Austria. (E.D., R.H., A.B., D. Lener, M.S., R.K., G.W., I.T.)
| | - Johannes Holfeld
- Department of Cardiac Surgery, Medical University of Innsbruck, Austria. (C.G.-T., M.G, J.H., S.M., L.P., F.N., E.K., N.F., D. Lobenwein, V.S., J.E., M.G., J.H.)
| |
Collapse
|
6
|
Contento L, Castelletti N, Raimúndez E, Le Gleut R, Schälte Y, Stapor P, Hinske LC, Hoelscher M, Wieser A, Radon K, Fuchs C, Hasenauer J. Integrative modelling of reported case numbers and seroprevalence reveals time-dependent test efficiency and infectious contacts. Epidemics 2023; 43:100681. [PMID: 36931114 PMCID: PMC10008049 DOI: 10.1016/j.epidem.2023.100681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2021] [Revised: 02/28/2023] [Accepted: 03/08/2023] [Indexed: 03/16/2023] Open
Abstract
Mathematical models have been widely used during the ongoing SARS-CoV-2 pandemic for data interpretation, forecasting, and policy making. However, most models are based on officially reported case numbers, which depend on test availability and test strategies. The time dependence of these factors renders interpretation difficult and might even result in estimation biases. Here, we present a computational modelling framework that allows for the integration of reported case numbers with seroprevalence estimates obtained from representative population cohorts. To account for the time dependence of infection and testing rates, we embed flexible splines in an epidemiological model. The parameters of these splines are estimated, along with the other parameters, from the available data using a Bayesian approach. The application of this approach to the official case numbers reported for Munich (Germany) and the seroprevalence reported by the prospective COVID-19 Cohort Munich (KoCo19) provides first estimates for the time dependence of the under-reporting factor. Furthermore, we estimate how the effectiveness of non-pharmaceutical interventions and of the testing strategy evolves over time. Overall, our results show that the integration of temporally highly resolved and representative data is beneficial for accurate epidemiological analyses.
Collapse
Affiliation(s)
- Lorenzo Contento
- Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany.
| | - Noemi Castelletti
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany
| | - Elba Raimúndez
- Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; Center for Mathematics, Technische Universität München, Garching, Germany
| | - Ronan Le Gleut
- Institute of Computational Biology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany; Core Facility Statistical Consulting, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany
| | - Yannik Schälte
- Institute of Computational Biology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany; Center for Mathematics, Technische Universität München, Garching, Germany
| | - Paul Stapor
- Institute of Computational Biology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany; Center for Mathematics, Technische Universität München, Garching, Germany
| | - Ludwig Christian Hinske
- Institut für medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Munich, Germany
| | - Michael Hoelscher
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany; Center for International Health (CIH), University Hospital, LMU Munich, Munich, Germany; German Center for Infection Research (DZIF), partner site Munich, Germany
| | - Andreas Wieser
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany; German Center for Infection Research (DZIF), partner site Munich, Germany
| | - Katja Radon
- German Center for Infection Research (DZIF), partner site Munich, Germany; Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, Munich, Germany; Comprehensive Pneumology Center (CPC) Munich, German Center for Lung Research (DZL), Munich, Germany
| | - Christiane Fuchs
- Institute of Computational Biology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany; Core Facility Statistical Consulting, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany; Center for Mathematics, Technische Universität München, Garching, Germany; Faculty of Business Administration and Economics, Bielefeld University, Bielefeld, Germany
| | - Jan Hasenauer
- Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany; Institute of Computational Biology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany; Center for Mathematics, Technische Universität München, Garching, Germany
| | | |
Collapse
|
7
|
Stalnaker KJ, Fuchs C, Slate A, Camacho JN, Pham L, Wang Y, Anderson RR, Tam J. Boot camp: Training and dressing regimens for modeling plantar wounds in the swine. Lab Anim 2023; 57:59-68. [PMID: 35962527 DOI: 10.1177/00236772221111058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Foot ulceration annually affects millions of patients and accounts for billions of dollars in medical expenses in the US alone. Many previous studies have investigated co-morbidities associated with impaired healing, such as microbial infection, compromised circulation, and diabetes. By comparison, little is known about how wound healing proceeds in plantar skin, despite its many unique specializations related to its load-bearing function. One of the main challenges in modeling plantar wounds is the difficulty in maintaining wound dressings, as animals generally have a low tolerance to wearing bandages on their feet. With assistance from the MGH Center for Comparative Medicine, we developed a positive reinforcement-based behavioral training regimen that successfully induced tolerance for plantar dressings in swine, which is a critical first step towards enabling in vivo study of the wound healing process in this highly specialized skin area. This training program will be described in detail in this manuscript.
Collapse
Affiliation(s)
| | - Christiane Fuchs
- Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, USA.,Department of Dermatology, Harvard Medical School, Boston, USA
| | - Andrea Slate
- Center for Comparative Medicine, Massachusetts General Hospital, Boston, USA
| | - Jennifer N Camacho
- Center for Comparative Medicine, Massachusetts General Hospital, Boston, USA
| | - Linh Pham
- Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, USA
| | - Ying Wang
- Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, USA.,Department of Dermatology, Harvard Medical School, Boston, USA
| | - R Rox Anderson
- Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, USA.,Department of Dermatology, Harvard Medical School, Boston, USA
| | - Joshua Tam
- Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, USA.,Department of Dermatology, Harvard Medical School, Boston, USA
| |
Collapse
|
8
|
Fuchs C, Stalnaker K, Wang Y, Pham L, Dalgard C, Cho S, Anderson R, Meyerle J, Tam J. 775 Structural and molecular similarities between plantar and wound keratinocytes - is the foot a chronic wound? J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.788] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
9
|
Tomasch J, Maleiner B, Heher P, Rufin M, Andriotis OG, Thurner PJ, Redl H, Fuchs C, Teuschl-Woller AH. Changes in Elastic Moduli of Fibrin Hydrogels Within the Myogenic Range Alter Behavior of Murine C2C12 and Human C25 Myoblasts Differently. Front Bioeng Biotechnol 2022; 10:836520. [PMID: 35669058 PMCID: PMC9164127 DOI: 10.3389/fbioe.2022.836520] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2021] [Accepted: 04/29/2022] [Indexed: 11/13/2022] Open
Abstract
Fibrin hydrogels have proven highly suitable scaffold materials for skeletal muscle tissue engineering in the past. Certain parameters of those types of scaffolds, however, greatly affect cellular mechanobiology and therefore the myogenic outcome. The aim of this study was to identify the influence of apparent elastic properties of fibrin scaffolds in 2D and 3D on myoblasts and evaluate if those effects differ between murine and human cells. Therefore, myoblasts were cultured on fibrin-coated multiwell plates (“2D”) or embedded in fibrin hydrogels (“3D”) with different elastic moduli. Firstly, we established an almost linear correlation between hydrogels’ fibrinogen concentrations and apparent elastic moduli in the range of 7.5 mg/ml to 30 mg/ml fibrinogen (corresponds to a range of 7.7–30.9 kPa). The effects of fibrin hydrogel elastic modulus on myoblast proliferation changed depending on culture type (2D vs 3D) with an inhibitory effect at higher fibrinogen concentrations in 3D gels and vice versa in 2D. The opposite effect was evident in differentiating myoblasts as shown by gene expression analysis of myogenesis marker genes and altered myotube morphology. Furthermore, culture in a 3D environment slowed down proliferation compared to 2D, with a significantly more pronounced effect on human myoblasts. Differentiation potential was also substantially impaired upon incorporation into 3D gels in human, but not in murine, myoblasts. With this study, we gained further insight in the influence of apparent elastic modulus and culture type on cellular behavior and myogenic outcome of skeletal muscle tissue engineering approaches. Furthermore, the results highlight the need to adapt parameters of 3D culture setups established for murine cells when applied to human cells.
Collapse
Affiliation(s)
- Janine Tomasch
- Department Life Science Engineering, University of Applied Sciences Technikum Wien, Vienna, Austria
- The Austrian Cluster for Tissue Regeneration, Vienna, Austria
- *Correspondence: Andreas H. Teuschl-Woller,
| | - Babette Maleiner
- Department Life Science Engineering, University of Applied Sciences Technikum Wien, Vienna, Austria
- The Austrian Cluster for Tissue Regeneration, Vienna, Austria
| | - Philipp Heher
- Ludwig Randall Centre for Cell and Molecular Biophysics, King’s College London, Guy’s Campus, London, United Kingdom
| | - Manuel Rufin
- The Austrian Cluster for Tissue Regeneration, Vienna, Austria
- Institute of Lightweight Design and Structural Biomechanics, TU Wien, Vienna, Austria
| | - Orestis G. Andriotis
- The Austrian Cluster for Tissue Regeneration, Vienna, Austria
- Institute of Lightweight Design and Structural Biomechanics, TU Wien, Vienna, Austria
| | - Philipp J. Thurner
- The Austrian Cluster for Tissue Regeneration, Vienna, Austria
- Institute of Lightweight Design and Structural Biomechanics, TU Wien, Vienna, Austria
| | - Heinz Redl
- The Austrian Cluster for Tissue Regeneration, Vienna, Austria
- Ludwig Boltzmann Institute for Traumatology, The Research Center in Cooperation with AUVA, Vienna, Austria
| | - Christiane Fuchs
- The Austrian Cluster for Tissue Regeneration, Vienna, Austria
- Wellman Center for Photomedicine, MGH, Boston, MA, United States
- Harvard Medical School, Boston, MA, United States
| | - Andreas H. Teuschl-Woller
- Department Life Science Engineering, University of Applied Sciences Technikum Wien, Vienna, Austria
- The Austrian Cluster for Tissue Regeneration, Vienna, Austria
- *Correspondence: Andreas H. Teuschl-Woller,
| |
Collapse
|
10
|
Pieschner S, Hasenauer J, Fuchs C. Identifiability analysis for models of the translation kinetics after mRNA transfection. J Math Biol 2022; 84:56. [PMID: 35577967 PMCID: PMC9110294 DOI: 10.1007/s00285-022-01739-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Revised: 03/25/2022] [Accepted: 03/26/2022] [Indexed: 11/12/2022]
Abstract
Mechanistic models are a powerful tool to gain insights into biological processes. The parameters of such models, e.g. kinetic rate constants, usually cannot be measured directly but need to be inferred from experimental data. In this article, we study dynamical models of the translation kinetics after mRNA transfection and analyze their parameter identifiability. That is, whether parameters can be uniquely determined from perfect or realistic data in theory and practice. Previous studies have considered ordinary differential equation (ODE) models of the process, and here we formulate a stochastic differential equation (SDE) model. For both model types, we consider structural identifiability based on the model equations and practical identifiability based on simulated as well as experimental data and find that the SDE model provides better parameter identifiability than the ODE model. Moreover, our analysis shows that even for those parameters of the ODE model that are considered to be identifiable, the obtained estimates are sometimes unreliable. Overall, our study clearly demonstrates the relevance of considering different modeling approaches and that stochastic models can provide more reliable and informative results.
Collapse
Affiliation(s)
- Susanne Pieschner
- Institute of Computational Biology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Oberschleißheim, Germany.,Department of Mathematics, Technical University Munich, Garching, Germany
| | - Jan Hasenauer
- Institute of Computational Biology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Oberschleißheim, Germany.,Department of Mathematics, Technical University Munich, Garching, Germany.,Faculty of Mathematics and Natural Sciences, University of Bonn, Bonn, Germany
| | - Christiane Fuchs
- Institute of Computational Biology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Oberschleißheim, Germany. .,Department of Mathematics, Technical University Munich, Garching, Germany. .,Faculty of Business Administration and Economics, Bielefeld University, Bielefeld, Germany.
| |
Collapse
|
11
|
Puchinger K, Castelletti N, Rubio-Acero R, Geldmacher C, Eser TM, Deák F, Paunovic I, Bakuli A, Saathoff E, von Meyer A, Markgraf A, Falk P, Reich J, Riess F, Girl P, Müller K, Radon K, Guggenbuehl Noller JM, Wölfel R, Hoelscher M, Kroidl I, Wieser A, Olbrich L, Alamoudi E, Anderson J, Baumann M, Behlen M, Beyerl J, Böhnlein R, Brauer A, Britz V, Bruger J, Caroli F, Contento L, Diekmannshemke J, Do A, Dobler G, Eberle U, Eckstein J, Frese J, Forster F, Frahnow T, Fröschl G, Geisenberger O, Gillig K, Heiber A, Hinske C, Hoefflin J, Hofberger T, Höfinger M, Hofmann L, Horn S, Huber K, Janke C, Kappl U, Kiani C, Kroidl A, Laxy M, Leidl R, Lindner F, Mayrhofer R, Mekota AM, Müller H, Metaxa D, Pattard L, Pletschette M, Prückner S, Pusl K, Raimúndez E, Rothe C, Schäfer N, Schandelmaier P, Schneider L, Schultz S, Schunk M, Schwettmann L, Seibold H, Sothmann P, Stapor P, Theis F, Thiel V, Thiesbrummel S, Thur N, Waibel J, Wallrauch C, Winter S, Wolff J, Wullinger P, Yaqine H, Zange S, Zeggini E, Zimmermann T, Zielke A, Ibraheem M, Ahmed M, Becker M, Diepers P, Schälte Y, Garí M, Pütz P, Pritsch M, Fingerle V, Le Gleut R, Gilberg L, Brand I, Diefenbach M, Eser T, Weinauer F, Martin S, Quenzel EM, Durner J, Girl P, Müller K, Radon K, Fuchs C, Hasenauer J. The interplay of viral loads, clinical presentation, and serological responses in SARS-CoV-2 – Results from a prospective cohort of outpatient COVID-19 cases. Virology 2022; 569:37-43. [PMID: 35245784 PMCID: PMC8855229 DOI: 10.1016/j.virol.2022.02.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2021] [Revised: 02/15/2022] [Accepted: 02/15/2022] [Indexed: 11/24/2022]
Abstract
Risk factors for disease progression and severity of SARS-CoV-2 infections require an understanding of acute and long-term virological and immunological dynamics. Fifty-one RT-PCR positive COVID-19 outpatients were recruited between May and December 2020 in Munich, Germany, and followed up at multiple defined timepoints for up to one year. RT-PCR and viral culture were performed and seroresponses measured. Participants were classified applying the WHO clinical progression scale. Short symptom to test time (median 5.0 days; p = 0.0016) and high viral loads (VL; median maximum VL: 3∙108 copies/mL; p = 0.0015) were indicative for viral culture positivity. Participants with WHO grade 3 at baseline had significantly higher VLs compared to those with WHO 1 and 2 (p = 0.01). VLs dropped fast within 1 week of symptom onset. Maximum VLs were positively correlated with the magnitude of Ro-N-Ig seroresponse (p = 0.022). Our results describe the dynamics of VLs and antibodies to SARS-CoV-2 in mild to moderate cases that can support public health measures during the ongoing global pandemic.
Collapse
|
12
|
Stegelmann F, Wille K, Busen H, Fuchs C, Schauer S, Sadjadian P, Becker T, Kolatzki V, Döhner H, Stadler R, Döhner K, Griesshammer M. Publisher Correction: Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - on behalf of the German Study Group-MPN. Leukemia 2021; 35:3635. [PMID: 34785798 PMCID: PMC8632683 DOI: 10.1038/s41375-021-01366-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Frank Stegelmann
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
| | - Kai Wille
- University Clinic for Hematology, Oncology, Haemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany
| | - Hannah Busen
- Faculty of Business Administration and Economics, Bielefeld University, Bielefeld, Germany.,Institute of Computational Biology, Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Neuherberg, Germany
| | - Christiane Fuchs
- Faculty of Business Administration and Economics, Bielefeld University, Bielefeld, Germany.,Institute of Computational Biology, Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Neuherberg, Germany
| | - Stefanie Schauer
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | - Parvis Sadjadian
- University Clinic for Hematology, Oncology, Haemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany
| | - Tatjana Becker
- University Clinic for Hematology, Oncology, Haemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany
| | - Vera Kolatzki
- University Clinic for Hematology, Oncology, Haemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany
| | - Hartmut Döhner
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | - Rudolf Stadler
- University Clinic for Dermatology, Venereology, Allergology and Phlebology, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany
| | | | - Konstanze Döhner
- Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany
| | - Martin Griesshammer
- University Clinic for Hematology, Oncology, Haemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany
| |
Collapse
|
13
|
Wille K, Huenerbein K, Jagenberg E, Sadjadian P, Becker T, Kolatzki V, Meixner R, Marchi H, Fuchs C, Griesshammer M. Bleeding complications in bcr-abl-negative myeloproliferative neoplasms (MPN): A retrospective single-center study of 829 MPN patients. Eur J Haematol 2021; 108:154-162. [PMID: 34719056 DOI: 10.1111/ejh.13721] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2021] [Revised: 10/23/2021] [Accepted: 10/25/2021] [Indexed: 12/17/2022]
Abstract
In patients with bcr-abl-negative myeloproliferative neoplasms (MPN), concerns are often raised about the use of anticoagulants because of an increased bleeding risk. However, there are few MPN studies focusing on bleeding. To investigate bleeding complications in MPN, we report our retrospective, single-center study of 829 patients with a median follow-up of 5.5 years (range: 0.1-35.6). A first bleeding event occurred in 143 of 829 patients (17.2%), corresponding to an incidence rate of 2.29% per patient/year. During the follow-up period, one out of 829 patients (0.1%) died due to bleeding. Regarding anticoagulation, most bleeding occurred in patients on antiplatelet therapies (60.1%), followed by patients on anticoagulation therapies (20.3%) and patients not on anticoagulation (19.6%). In multivariate analysis, administration of antiplatelet (HR 2.31 [1.43, 3.71]) and anticoagulation therapies (HR 4.06 [2.32, 7.09]), but not age, gender or mutation status, was associated with an increased bleeding risk. Comparing the "probability of bleeding-free survival" between the MPN subtypes, no significant difference was observed (p = 0.91, log-rank test). Our retrospective study shows that antiplatelet and anticoagulation therapies significantly increase the risk of bleeding in MPN patients without affecting mortality. However, there is no reason to refrain from guideline-conform primary or secondary anticoagulation in MPN patients.
Collapse
Affiliation(s)
- Kai Wille
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany
| | - Karlo Huenerbein
- University Institute for Anesthesiology, Intensive Care and Emergency Medicine, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany
| | - Ellen Jagenberg
- University Institute for Anesthesiology, Intensive Care and Emergency Medicine, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany
| | - Parvis Sadjadian
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany
| | - Tatjana Becker
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany
| | - Vera Kolatzki
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany
| | - Raphael Meixner
- Institute of Computational Biology, Helmholtz Center Munich, Neuherberg, Germany
| | - Hannah Marchi
- Institute of Computational Biology, Helmholtz Center Munich, Neuherberg, Germany.,Bielefeld University, Bielefeld, Germany
| | - Christiane Fuchs
- Institute of Computational Biology, Helmholtz Center Munich, Neuherberg, Germany.,Bielefeld University, Bielefeld, Germany
| | - Martin Griesshammer
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Minden, Germany
| |
Collapse
|
14
|
Fuchs C, Pham L, Wang Y, Farinelli WA, Anderson RR, Tam J. MagneTEskin-Reconstructing skin by magnetically induced assembly of autologous microtissue cores. Sci Adv 2021; 7:eabj0864. [PMID: 34623914 PMCID: PMC8500515 DOI: 10.1126/sciadv.abj0864] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Abstract
Skin wounds are immense medical and socioeconomic burdens, and autologous skin grafting remains the gold standard for wound repair. We recently found that full-thickness micro skin tissue columns (MSTCs) can be harvested with minimal donor site morbidity, and that MSTCs applied to wounds “randomly” (without maintaining their natural epidermal-dermal orientation) can accelerate re-epithelialization. However, despite MSTCs containing all the cellular and extracellular contents of full-thickness skin, normal dermal architecture was not restored by random MSTCs. In this study, we developed a magnetically induced assembly method to produce constructs of densely packed, oriented MSTCs that closely resemble the overall architecture of full-thickness skin to test the hypothesis that maintaining MSTCs’ orientation could further hasten healing and restore a normal dermis. Our method led to faster and more orderly re-epithelialization but unexpectedly did not improve the retention of dermal architecture, which reveals a hitherto unappreciated role for tissue morphology in determining dermal remodeling outcomes.
Collapse
Affiliation(s)
- Christiane Fuchs
- Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114, USA
- Department of Dermatology, Harvard Medical School, Boston, MA 02115, USA
| | - Linh Pham
- Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114, USA
| | - Ying Wang
- Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114, USA
- Department of Dermatology, Harvard Medical School, Boston, MA 02115, USA
| | - William A. Farinelli
- Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114, USA
| | - R. Rox Anderson
- Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114, USA
- Department of Dermatology, Harvard Medical School, Boston, MA 02115, USA
| | - Joshua Tam
- Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114, USA
- Department of Dermatology, Harvard Medical School, Boston, MA 02115, USA
- Corresponding author.
| |
Collapse
|
15
|
Olbrich L, Castelletti N, Schälte Y, Garí M, Pütz P, Bakuli A, Pritsch M, Kroidl I, Saathoff E, Guggenbuehl Noller JM, Fingerle V, Le Gleut R, Gilberg L, Brand I, Falk P, Markgraf A, Deák F, Riess F, Diefenbach M, Eser T, Weinauer F, Martin S, Quenzel EM, Becker M, Durner J, Girl P, Müller K, Radon K, Fuchs C, Wölfel R, Hasenauer J, Hoelscher M, Wieser A. Head-to-head evaluation of seven different seroassays including direct viral neutralisation in a representative cohort for SARS-CoV-2. J Gen Virol 2021; 102:001653. [PMID: 34623233 PMCID: PMC8604188 DOI: 10.1099/jgv.0.001653] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2021] [Accepted: 07/20/2021] [Indexed: 12/21/2022] Open
Abstract
A number of seroassays are available for SARS-CoV-2 testing; yet, head-to-head evaluations of different testing principles are limited, especially using raw values rather than categorical data. In addition, identifying correlates of protection is of utmost importance, and comparisons of available testing systems with functional assays, such as direct viral neutralisation, are needed.We analysed 6658 samples consisting of true-positives (n=193), true-negatives (n=1091), and specimens of unknown status (n=5374). For primary testing, we used Euroimmun-Anti-SARS-CoV-2-ELISA-IgA/IgG and Roche-Elecsys-Anti-SARS-CoV-2. Subsequently virus-neutralisation, GeneScriptcPass, VIRAMED-SARS-CoV-2-ViraChip, and Mikrogen-recomLine-SARS-CoV-2-IgG were applied for confirmatory testing. Statistical modelling generated optimised assay cut-off thresholds. Sensitivity of Euroimmun-anti-S1-IgA was 64.8%, specificity 93.3% (manufacturer's cut-off); for Euroimmun-anti-S1-IgG, sensitivity was 77.2/79.8% (manufacturer's/optimised cut-offs), specificity 98.0/97.8%; Roche-anti-N sensitivity was 85.5/88.6%, specificity 99.8/99.7%. In true-positives, mean and median Euroimmun-anti-S1-IgA and -IgG titres decreased 30/90 days after RT-PCR-positivity, Roche-anti-N titres decreased significantly later. Virus-neutralisation was 80.6% sensitive, 100.0% specific (≥1:5 dilution). Neutralisation surrogate tests (GeneScriptcPass, Mikrogen-recomLine-RBD) were >94.9% sensitive and >98.1% specific. Optimised cut-offs improved test performances of several tests. Confirmatory testing with virus-neutralisation might be complemented with GeneScriptcPassTM or recomLine-RBD for certain applications. Head-to-head comparisons given here aim to contribute to the refinement of testing strategies for individual and public health use.
Collapse
Affiliation(s)
- Laura Olbrich
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany
- German Center for Infection Research (DZIF), Partner site Munich, Germany
| | - Noemi Castelletti
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany
- Institute of Radiation Medicine, Helmholtz Zentrum München, 85764 Neuherberg, Germany
| | - Yannik Schälte
- Institute of Computational Biology, Helmholtz Zentrum München, 85764 Neuherberg, Germany
- Center for Mathematics, Technische Universität München, 85748 Garching, Germany
| | - Mercè Garí
- Institute of Computational Biology, Helmholtz Zentrum München, 85764 Neuherberg, Germany
| | - Peter Pütz
- Institute of Computational Biology, Helmholtz Zentrum München, 85764 Neuherberg, Germany
- Department of Business Administration and Economics, Bielefeld University, 33615 Bielefeld, Germany
| | - Abhishek Bakuli
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany
| | - Michael Pritsch
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany
| | - Inge Kroidl
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany
- German Center for Infection Research (DZIF), Partner site Munich, Germany
| | - Elmar Saathoff
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany
- German Center for Infection Research (DZIF), Partner site Munich, Germany
| | | | - Volker Fingerle
- German Center for Infection Research (DZIF), Partner site Munich, Germany
- Bavarian Health and Food Safety Authority (LGL), Germany
| | - Ronan Le Gleut
- Institute of Computational Biology, Helmholtz Zentrum München, 85764 Neuherberg, Germany
- Core Facility Statistical Consulting, Helmholtz Zentrum München, 85764 Neuherberg, Germany
| | - Leonard Gilberg
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany
| | - Isabel Brand
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany
| | - Philine Falk
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany
| | - Alisa Markgraf
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany
| | - Flora Deák
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany
| | - Friedrich Riess
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany
| | - Max Diefenbach
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany
| | - Tabea Eser
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany
| | | | | | | | - Marc Becker
- Department of Conservative Dentistry and Periodontology, University Hospital, LMU Munich Ludwig-Maximilians-University of Munich, Goethestr. 70, 80336 Munich, Germany
- Laboratory Becker and colleagues, Führichstr. 70, 81671 München, Germany
| | - Jürgen Durner
- Department of Conservative Dentistry and Periodontology, University Hospital, LMU Munich Ludwig-Maximilians-University of Munich, Goethestr. 70, 80336 Munich, Germany
- Laboratory Becker and colleagues, Führichstr. 70, 81671 München, Germany
| | - Philipp Girl
- German Center for Infection Research (DZIF), Partner site Munich, Germany
- Bundeswehr Institute of Microbiology, 80937 Munich, Germany
| | - Katharina Müller
- German Center for Infection Research (DZIF), Partner site Munich, Germany
- Bundeswehr Institute of Microbiology, 80937 Munich, Germany
| | - Katja Radon
- Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, 80336 Munich, Germany
- Center for International Health (CIH), University Hospital, LMU Munich, 80336 Munich, Germany
- Comprehensive Pneumology Center (CPC) Munich, German Center for Lung Research (DZL), 80337 Munich, Germany
| | - Christiane Fuchs
- Institute of Computational Biology, Helmholtz Zentrum München, 85764 Neuherberg, Germany
- Center for Mathematics, Technische Universität München, 85748 Garching, Germany
- Department of Business Administration and Economics, Bielefeld University, 33615 Bielefeld, Germany
- Core Facility Statistical Consulting, Helmholtz Zentrum München, 85764 Neuherberg, Germany
| | - Roman Wölfel
- German Center for Infection Research (DZIF), Partner site Munich, Germany
- Bundeswehr Institute of Microbiology, 80937 Munich, Germany
| | - Jan Hasenauer
- Institute of Computational Biology, Helmholtz Zentrum München, 85764 Neuherberg, Germany
- Center for Mathematics, Technische Universität München, 85748 Garching, Germany
- Faculty of Mathematics and Natural Sciences, University of Bonn, 53113 Bonn, Germany
| | - Michael Hoelscher
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany
- German Center for Infection Research (DZIF), Partner site Munich, Germany
- Center for International Health (CIH), University Hospital, LMU Munich, 80336 Munich, Germany
| | - Andreas Wieser
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany
- German Center for Infection Research (DZIF), Partner site Munich, Germany
| | - on behalf of the KoCo19-Study Group
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany
- German Center for Infection Research (DZIF), Partner site Munich, Germany
- Institute of Radiation Medicine, Helmholtz Zentrum München, 85764 Neuherberg, Germany
- Institute of Computational Biology, Helmholtz Zentrum München, 85764 Neuherberg, Germany
- Center for Mathematics, Technische Universität München, 85748 Garching, Germany
- Department of Business Administration and Economics, Bielefeld University, 33615 Bielefeld, Germany
- Bavarian Health and Food Safety Authority (LGL), Germany
- Core Facility Statistical Consulting, Helmholtz Zentrum München, 85764 Neuherberg, Germany
- BRK-Blutspendedienst, 80336 Munich, Germany
- Department of Conservative Dentistry and Periodontology, University Hospital, LMU Munich Ludwig-Maximilians-University of Munich, Goethestr. 70, 80336 Munich, Germany
- Laboratory Becker and colleagues, Führichstr. 70, 81671 München, Germany
- Bundeswehr Institute of Microbiology, 80937 Munich, Germany
- Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, 80336 Munich, Germany
- Center for International Health (CIH), University Hospital, LMU Munich, 80336 Munich, Germany
- Comprehensive Pneumology Center (CPC) Munich, German Center for Lung Research (DZL), 80337 Munich, Germany
- Faculty of Mathematics and Natural Sciences, University of Bonn, 53113 Bonn, Germany
| |
Collapse
|
16
|
Radon K, Bakuli A, Pütz P, Le Gleut R, Guggenbuehl Noller JM, Olbrich L, Saathoff E, Garí M, Schälte Y, Frahnow T, Wölfel R, Pritsch M, Rothe C, Pletschette M, Rubio-Acero R, Beyerl J, Metaxa D, Forster F, Thiel V, Castelletti N, Rieß F, Diefenbach MN, Fröschl G, Bruger J, Winter S, Frese J, Puchinger K, Brand I, Kroidl I, Wieser A, Hoelscher M, Hasenauer J, Fuchs C. From first to second wave: follow-up of the prospective COVID-19 cohort (KoCo19) in Munich (Germany). BMC Infect Dis 2021; 21:925. [PMID: 34493217 PMCID: PMC8423599 DOI: 10.1186/s12879-021-06589-4] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2021] [Accepted: 08/19/2021] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND In the 2nd year of the COVID-19 pandemic, knowledge about the dynamics of the infection in the general population is still limited. Such information is essential for health planners, as many of those infected show no or only mild symptoms and thus, escape the surveillance system. We therefore aimed to describe the course of the pandemic in the Munich general population living in private households from April 2020 to January 2021. METHODS The KoCo19 baseline study took place from April to June 2020 including 5313 participants (age 14 years and above). From November 2020 to January 2021, we could again measure SARS-CoV-2 antibody status in 4433 of the baseline participants (response 83%). Participants were offered a self-sampling kit to take a capillary blood sample (dry blood spot; DBS). Blood was analysed using the Elecsys® Anti-SARS-CoV-2 assay (Roche). Questionnaire information on socio-demographics and potential risk factors assessed at baseline was available for all participants. In addition, follow-up information on health-risk taking behaviour and number of personal contacts outside the household (N = 2768) as well as leisure time activities (N = 1263) were collected in summer 2020. RESULTS Weighted and adjusted (for specificity and sensitivity) SARS-CoV-2 sero-prevalence at follow-up was 3.6% (95% CI 2.9-4.3%) as compared to 1.8% (95% CI 1.3-3.4%) at baseline. 91% of those tested positive at baseline were also antibody-positive at follow-up. While sero-prevalence increased from early November 2020 to January 2021, no indication of geospatial clustering across the city of Munich was found, although cases clustered within households. Taking baseline result and time to follow-up into account, men and participants in the age group 20-34 years were at the highest risk of sero-positivity. In the sensitivity analyses, differences in health-risk taking behaviour, number of personal contacts and leisure time activities partly explained these differences. CONCLUSION The number of citizens in Munich with SARS-CoV-2 antibodies was still below 5% during the 2nd wave of the pandemic. Antibodies remained present in the majority of SARS-CoV-2 sero-positive baseline participants. Besides age and sex, potentially confounded by differences in behaviour, no major risk factors could be identified. Non-pharmaceutical public health measures are thus still important.
Collapse
Affiliation(s)
- Katja Radon
- Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, 80336, Munich, Germany.
- Center for International Health (CIH), University Hospital, LMU Munich, 80336, Munich, Germany.
- Comprehensive Pneumology Center (CPC) Munich, German Center for Lung Research (DZL), 89337, Munich, Germany.
| | - Abhishek Bakuli
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
| | - Peter Pütz
- Institute of Computational Biology, Helmholtz Zentrum München-German Research Center for Environmental Health, 85764, Neuherberg, Germany
- Faculty of Business Administration and Economics, Bielefeld University, 33615, Bielefeld, Germany
| | - Ronan Le Gleut
- Institute of Computational Biology, Helmholtz Zentrum München-German Research Center for Environmental Health, 85764, Neuherberg, Germany
- Core Facility Statistical Consulting, Helmholtz Zentrum München-German Research Center for Environmental Health, 85764, Neuherberg, Germany
| | | | - Laura Olbrich
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
- German Center for Infection Research (DZIF), partner site, Munich, Germany
| | - Elmar Saathoff
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
- German Center for Infection Research (DZIF), partner site, Munich, Germany
| | - Mercè Garí
- Institute of Computational Biology, Helmholtz Zentrum München-German Research Center for Environmental Health, 85764, Neuherberg, Germany
| | - Yannik Schälte
- Institute of Computational Biology, Helmholtz Zentrum München-German Research Center for Environmental Health, 85764, Neuherberg, Germany
- Center for Mathematics, Technische Universität München, 85748, Garching, Germany
| | - Turid Frahnow
- Institute of Computational Biology, Helmholtz Zentrum München-German Research Center for Environmental Health, 85764, Neuherberg, Germany
- Faculty of Business Administration and Economics, Bielefeld University, 33615, Bielefeld, Germany
| | - Roman Wölfel
- German Center for Infection Research (DZIF), partner site, Munich, Germany
- Bundeswehr Institute of Microbiology, 80937, Munich, Germany
| | - Michael Pritsch
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
- German Center for Infection Research (DZIF), partner site, Munich, Germany
| | - Camilla Rothe
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
| | - Michel Pletschette
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
| | - Raquel Rubio-Acero
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
| | - Jessica Beyerl
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
| | - Dafni Metaxa
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
| | - Felix Forster
- Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, 80336, Munich, Germany
- Comprehensive Pneumology Center (CPC) Munich, German Center for Lung Research (DZL), 89337, Munich, Germany
| | - Verena Thiel
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
| | - Noemi Castelletti
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
| | - Friedrich Rieß
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
- German Center for Infection Research (DZIF), partner site, Munich, Germany
| | - Maximilian N Diefenbach
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
| | - Günter Fröschl
- Center for International Health (CIH), University Hospital, LMU Munich, 80336, Munich, Germany
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
| | - Jan Bruger
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
| | - Simon Winter
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
| | - Jonathan Frese
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
| | - Kerstin Puchinger
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
| | - Isabel Brand
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
| | - Inge Kroidl
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
- German Center for Infection Research (DZIF), partner site, Munich, Germany
| | - Andreas Wieser
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
- German Center for Infection Research (DZIF), partner site, Munich, Germany
| | - Michael Hoelscher
- Center for International Health (CIH), University Hospital, LMU Munich, 80336, Munich, Germany
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802, Munich, Germany
- German Center for Infection Research (DZIF), partner site, Munich, Germany
| | - Jan Hasenauer
- Institute of Computational Biology, Helmholtz Zentrum München-German Research Center for Environmental Health, 85764, Neuherberg, Germany
- Center for Mathematics, Technische Universität München, 85748, Garching, Germany
- Interdisciplinary Research Unit Mathematics and Life Sciences, University of Bonn, 53113, Bonn, Germany
| | - Christiane Fuchs
- Institute of Computational Biology, Helmholtz Zentrum München-German Research Center for Environmental Health, 85764, Neuherberg, Germany
- Faculty of Business Administration and Economics, Bielefeld University, 33615, Bielefeld, Germany
- Core Facility Statistical Consulting, Helmholtz Zentrum München-German Research Center for Environmental Health, 85764, Neuherberg, Germany
- Center for Mathematics, Technische Universität München, 85748, Garching, Germany
| |
Collapse
|
17
|
Cohen R, Shi Q, Meyers J, Jin Z, Svrcek M, Fuchs C, Couture F, Kuebler P, Ciombor KK, Bendell J, De Jesus-Acosta A, Kumar P, Lewis D, Tan B, Bertagnolli MM, Philip P, Blanke C, O'Reilly EM, Shields A, Meyerhardt JA. Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 phase III study (Alliance) ☆. Ann Oncol 2021; 32:1267-1275. [PMID: 34293461 DOI: 10.1016/j.annonc.2021.07.009] [Citation(s) in RCA: 39] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2021] [Revised: 07/14/2021] [Accepted: 07/15/2021] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND In colon cancer, tumor deposits (TD) are considered in assigning prognosis and staging only in the absence of lymph node metastasis (i.e. stage III pN1c tumors). We aimed to evaluate the prognostic value of the presence and the number of TD in patients with stage III, node-positive colon cancer. PATIENTS AND METHODS All participants from the CALGB/SWOG 80702 phase III trial were included in this post hoc analysis. Pathology reports were reviewed for the presence and the number of TD, lymphovascular and perineural invasion. Associations with disease-free survival (DFS) and overall survival (OS) were evaluated by multivariable Cox models adjusting for sex, treatment arm, T-stage, N-stage, lymphovascular invasion, perineural invasion and lymph node ratio. RESULTS Overall, 2028 patients were included with 524 (26%) TD-positive and 1504 (74%) TD-negative tumors. Of the TD-positive patients, 80 (15.4%) were node negative (i.e. pN1c), 239 (46.1%) were pN1a/b (<4 positive lymph nodes) and 200 (38.5%) were pN2 (≥4 positive lymph nodes). The presence of TD was associated with poorer DFS [adjusted hazard ratio (aHR) = 1.63, 95% CI 1.33-1.98] and OS (aHR = 1.59, 95% CI 1.24-2.04). The negative effect of TD was observed for both pN1a/b and pN2 groups. Among TD-positive patients, the number of TD had a linear negative effect on DFS and OS. Combining TD and the number of lymph node metastases, 104 of 1470 (7.1%) pN1 patients were re-staged as pN2, with worse outcomes than patients confirmed as pN1 (3-year DFS rate: 65.4% versus 80.5%, P = 0.0003; 5-year OS rate: 87.9% versus 69.1%, P = <0.0001). DFS was not different between patients re-staged as pN2 and those initially staged as pN2 (3-year DFS rate: 65.4% versus 62.3%, P = 0.4895). CONCLUSION Combining the number of TD and the number of lymph node metastases improved the prognostication accuracy of tumor-node-metastasis (TNM) staging.
Collapse
Affiliation(s)
- R Cohen
- Department of Health Science Research, Mayo Clinic, Rochester, USA; Sorbonne Université, Department of Medical Oncology, Saint-Antoine Hospital, Paris, France; Sorbonne Université, INSERM, Unité Mixte de Recherche Scientifique 938, Centre de Recherche Saint-Antoine, Equipe Instabilité des Microsatellites et Cancer, Equipe labellisée par la Ligue Nationale contre le Cancer, Paris, France.
| | - Q Shi
- Alliance Statistics and Data Center, Mayo Clinic, Rochester, USA
| | - J Meyers
- Alliance Statistics and Data Center, Mayo Clinic, Rochester, USA
| | - Z Jin
- Division of Oncology, Mayo Clinic and Mayo Comprehensive Cancer Center, Rochester, USA
| | - M Svrcek
- Sorbonne Université, INSERM, Unité Mixte de Recherche Scientifique 938, Centre de Recherche Saint-Antoine, Equipe Instabilité des Microsatellites et Cancer, Equipe labellisée par la Ligue Nationale contre le Cancer, Paris, France; Sorbonne Université, Department of Pathology, Saint-Antoine Hospital, Paris, France
| | - C Fuchs
- Genentech, South San Francisco, USA; Division of Hematology and Medical Oncology, Department of Internal Medicine, Yale School of Medicine, and Yale Cancer Center, New Haven, USA
| | - F Couture
- Hôtel-Dieu de Québec, Quebec, Canada
| | - P Kuebler
- Columbus NCI Community Clinical Oncology Research Program, Columbus, USA
| | - K K Ciombor
- Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, USA
| | - J Bendell
- Sarah Cannon Research Institute/Tennessee Oncology, Nashville, USA
| | - A De Jesus-Acosta
- Department of Medical Oncology, John Hopkins University, Baltimore, USA
| | - P Kumar
- Illinois Cancercare, P.C., Peoria, USA
| | - D Lewis
- Southeast Clinical Oncology Research, Cone Health Medical Group, Asheboro, USA
| | - B Tan
- Siteman Cancer Center, Washington University School of Medicine, St. Louis, USA
| | - M M Bertagnolli
- Office of the Alliance Group Chair, Brigham and Women's Hospital, Boston, USA
| | - P Philip
- Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, USA
| | - C Blanke
- SWOG Cancer Research Network Group Chair's Office, Oregon Health and Science University Knight Cancer Institute, Portland, USA
| | - E M O'Reilly
- Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical Center, New York, USA
| | - A Shields
- Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, USA
| | - J A Meyerhardt
- Department of Medical Oncology, Dana-Farber/Partners Cancer Care, Boston, USA
| |
Collapse
|
18
|
Brand I, Gilberg L, Bruger J, Garí M, Wieser A, Eser TM, Frese J, Ahmed MIM, Rubio-Acero R, Guggenbuehl Noller JM, Castelletti N, Diekmannshemke J, Thiesbrummel S, Huynh D, Winter S, Kroidl I, Fuchs C, Hoelscher M, Roider J, Kobold S, Pritsch M, Geldmacher C. Broad T Cell Targeting of Structural Proteins After SARS-CoV-2 Infection: High Throughput Assessment of T Cell Reactivity Using an Automated Interferon Gamma Release Assay. Front Immunol 2021; 12:688436. [PMID: 34093595 PMCID: PMC8173205 DOI: 10.3389/fimmu.2021.688436] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2021] [Accepted: 04/30/2021] [Indexed: 11/13/2022] Open
Abstract
Background Adaptive immune responses to structural proteins of the virion play a crucial role in protection against coronavirus disease 2019 (COVID-19). We therefore studied T cell responses against multiple SARS-CoV-2 structural proteins in a large cohort using a simple, fast, and high-throughput approach. Methods An automated interferon gamma release assay (IGRA) for the Nucleocapsid (NC)-, Membrane (M)-, Spike-C-terminus (SCT)-, and N-terminus-protein (SNT)-specific T cell responses was performed using fresh whole blood from study subjects with convalescent, confirmed COVID-19 (n = 177, more than 200 days post infection), exposed household members (n = 145), and unexposed controls (n = 85). SARS-CoV-2-specific antibodies were assessed using Elecsys® Anti-SARS-CoV-2 (Ro-N-Ig) and Anti-SARS-CoV-2-ELISA (IgG) (EI-S1-IgG). Results 156 of 177 (88%) previously PCR confirmed cases were still positive by Ro-N-Ig more than 200 days after infection. In T cells, most frequently the M-protein was targeted by 88% seropositive, PCR confirmed cases, followed by SCT (85%), NC (82%), and SNT (73%), whereas each of these antigens was recognized by less than 14% of non-exposed control subjects. Broad targeting of these structural virion proteins was characteristic of convalescent SARS-CoV-2 infection; 68% of all seropositive individuals targeted all four tested antigens. Indeed, anti-NC antibody titer correlated loosely, but significantly with the magnitude and breadth of the SARS-CoV-2-specific T cell response. Age, sex, and body mass index were comparable between the different groups. Conclusion SARS-CoV-2 seropositivity correlates with broad T cell reactivity of the structural virus proteins at 200 days after infection and beyond. The SARS-CoV-2-IGRA can facilitate large scale determination of SARS-CoV-2-specific T cell responses with high accuracy against multiple targets.
Collapse
Affiliation(s)
- Isabel Brand
- Division of Infectious Diseases and Tropical Medicine, University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany
- Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, LMU Munich, Munich, Germany
| | - Leonard Gilberg
- Division of Infectious Diseases and Tropical Medicine, University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany
- Department of Infectious Diseases, University Hospital, LMU Munich, Munich, Germany
| | - Jan Bruger
- Division of Infectious Diseases and Tropical Medicine, University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany
| | - Mercè Garí
- Institute of Computational Biology, Helmholtz Zentrum München – German Research Center for Environmental Health (HMGU), Neuherberg, Germany
| | - Andreas Wieser
- Division of Infectious Diseases and Tropical Medicine, University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany
- German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany
| | - Tabea M. Eser
- Division of Infectious Diseases and Tropical Medicine, University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany
- German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany
| | - Jonathan Frese
- Division of Infectious Diseases and Tropical Medicine, University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany
| | - Mohamed I. M. Ahmed
- Division of Infectious Diseases and Tropical Medicine, University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany
- German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany
| | - Raquel Rubio-Acero
- Division of Infectious Diseases and Tropical Medicine, University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany
| | - Jessica M. Guggenbuehl Noller
- Division of Infectious Diseases and Tropical Medicine, University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany
| | - Noemi Castelletti
- Division of Infectious Diseases and Tropical Medicine, University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany
| | - Jana Diekmannshemke
- Institute of Computational Biology, Helmholtz Zentrum München – German Research Center for Environmental Health (HMGU), Neuherberg, Germany
- Faculty of Business Administration and Economics, Bielefeld University, Bielefeld, Germany
| | - Sophie Thiesbrummel
- Institute of Computational Biology, Helmholtz Zentrum München – German Research Center for Environmental Health (HMGU), Neuherberg, Germany
- Faculty of Business Administration and Economics, Bielefeld University, Bielefeld, Germany
| | - Duc Huynh
- Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, LMU Munich, Munich, Germany
| | - Simon Winter
- Division of Infectious Diseases and Tropical Medicine, University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany
| | - Inge Kroidl
- Division of Infectious Diseases and Tropical Medicine, University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany
- German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany
| | - Christiane Fuchs
- Institute of Computational Biology, Helmholtz Zentrum München – German Research Center for Environmental Health (HMGU), Neuherberg, Germany
- Faculty of Business Administration and Economics, Bielefeld University, Bielefeld, Germany
- Center for Mathematics, Technische Universität München, Garching, Germany
| | - Michael Hoelscher
- Division of Infectious Diseases and Tropical Medicine, University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany
- German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany
- Center for International Health (CIH), University Hospital, LMU Munich, Munich, Germany
| | - Julia Roider
- Department of Infectious Diseases, University Hospital, LMU Munich, Munich, Germany
- German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany
| | - Sebastian Kobold
- Division of Clinical Pharmacology, Department of Medicine IV, University Hospital, LMU Munich, Munich, Germany
- German Center for Translational Cancer Research (DKTK), Partner Site Munich, Munich, Germany
- Unit for Clinical Pharmacology (EKLiP), Helmholtz Zentrum München – German Research Center for Environmental Health (HMGU), Neuherberg, Germany
| | - Michael Pritsch
- Division of Infectious Diseases and Tropical Medicine, University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany
- German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany
| | - Christof Geldmacher
- Division of Infectious Diseases and Tropical Medicine, University Hospital, Ludwig-Maximilians-Universität (LMU) Munich, Munich, Germany
- German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany
| |
Collapse
|
19
|
Fuchs C, Schenk MS, Pham L, Cui L, Anderson RR, Tam J. Photobiomodulation Response From 660 nm is Different and More Durable Than That From 980 nm. Lasers Surg Med 2021; 53:1279-1293. [PMID: 33998008 DOI: 10.1002/lsm.23419] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2020] [Revised: 03/28/2021] [Accepted: 04/24/2021] [Indexed: 12/14/2022]
Abstract
BACKGROUND AND OBJECTIVES Photobiomodulation (PBM) therapy uses light at various wavelengths to stimulate wound healing, grow hair, relieve pain, and more-but there is no consensus about optimal wavelengths or dosimetry. PBM therapy works through putative, wavelength-dependent mechanisms including direct stimulation of mitochondrial respiration, and/or activation of transmembrane signaling channels by changes in water activity. A common wavelength used in the visible red spectrum is ~660 nm, whereas recently ~980 nm is being explored and both have been proposed to work via different mechanisms. We aimed to gain more insight into identifying treatment parameters and the putative mechanisms involved. STUDY DESIGN/MATERIALS AND METHODS Fluence-response curves were measured in cultured keratinocytes and fibroblasts exposed to 660 or 980 nm from LED sources. Metabolic activity was assessed using the MTT assay for reductases. ATP production, a major event triggered by PBM therapy, was assessed using a luminescence assay. To measure the role of mitochondria, we used an ELISA to measure COX-1 and SDH-A protein levels. The respective contributions of cytochrome c oxidase and ATP synthase to the PBM effects were gauged using specific inhibitors. RESULTS Keratinocytes and fibroblasts responded differently to exposures at 660 nm (red) and 980 nm (NIR). Although 980 nm required much lower fluence for cell stimulation, the resulting increase in ATP levels was short-term, whereas 660 nm stimulation elevated ATP levels for at least 24 hours. COX-1 protein levels were increased following 660 nm treatment but were unaffected by 980 nm. In fibroblasts, SDH-A levels were affected by both wavelengths, whereas in keratinocytes only 660 nm light impacted SDH-A levels. Inhibition of ATP synthase nearly completely abolished the effects of both wavelengths on ATP synthesis. Interestingly, inhibiting cytochrome c oxidase did not prevent the rise in ATP levels in response to PBM treatment. CONCLUSION To the best of our knowledge, this is the first demonstration of differing kinetics in response to PBM therapy at red versus NIR wavelength. We also found cell-type-specific differences in PBM therapy response to the two wavelengths studied. These findings confirm that different response pathways are involved after 660 and 980 nm exposures and suggest that 660 nm causes a more durable response. © 2021 Wiley Periodicals LLC.
Collapse
Affiliation(s)
- Christiane Fuchs
- Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts, 02114.,Department of Dermatology, Harvard Medical School, Boston, Massachusetts, 02115
| | - Merle Sophie Schenk
- Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts, 02114
| | - Linh Pham
- Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts, 02114
| | - Lian Cui
- Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts, 02114
| | - Richard Rox Anderson
- Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts, 02114.,Department of Dermatology, Harvard Medical School, Boston, Massachusetts, 02115
| | - Joshua Tam
- Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts, 02114.,Department of Dermatology, Harvard Medical School, Boston, Massachusetts, 02115
| |
Collapse
|
20
|
Pritsch M, Radon K, Bakuli A, Le Gleut R, Olbrich L, Guggenbüehl Noller JM, Saathoff E, Castelletti N, Garí M, Pütz P, Schälte Y, Frahnow T, Wölfel R, Rothe C, Pletschette M, Metaxa D, Forster F, Thiel V, Rieß F, Diefenbach MN, Fröschl G, Bruger J, Winter S, Frese J, Puchinger K, Brand I, Kroidl I, Hasenauer J, Fuchs C, Wieser A, Hoelscher M. Prevalence and Risk Factors of Infection in the Representative COVID-19 Cohort Munich. Int J Environ Res Public Health 2021; 18:ijerph18073572. [PMID: 33808249 PMCID: PMC8038115 DOI: 10.3390/ijerph18073572] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/18/2021] [Revised: 03/23/2021] [Accepted: 03/27/2021] [Indexed: 02/07/2023]
Abstract
Given the large number of mild or asymptomatic SARS-CoV-2 cases, only population-based studies can provide reliable estimates of the magnitude of the pandemic. We therefore aimed to assess the sero-prevalence of SARS-CoV-2 in the Munich general population after the first wave of the pandemic. For this purpose, we drew a representative sample of 2994 private households and invited household members 14 years and older to complete questionnaires and to provide blood samples. SARS-CoV-2 seropositivity was defined as Roche N pan-Ig ≥ 0.4218. We adjusted the prevalence for the sampling design, sensitivity, and specificity. We investigated risk factors for SARS-CoV-2 seropositivity and geospatial transmission patterns by generalized linear mixed models and permutation tests. Seropositivity for SARS-CoV-2-specific antibodies was 1.82% (95% confidence interval (CI) 1.28-2.37%) as compared to 0.46% PCR-positive cases officially registered in Munich. Loss of the sense of smell or taste was associated with seropositivity (odds ratio (OR) 47.4; 95% CI 7.2-307.0) and infections clustered within households. By this first population-based study on SARS-CoV-2 prevalence in a large German municipality not affected by a superspreading event, we could show that at least one in four cases in private households was reported and known to the health authorities. These results will help authorities to estimate the true burden of disease in the population and to take evidence-based decisions on public health measures.
Collapse
Affiliation(s)
- Michael Pritsch
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany; (M.P.); (A.B.); (L.O.); (J.M.G.N.); (E.S.); (N.C.); (C.R.); (M.P.); (D.M.); (V.T.); (F.R.); (M.N.D.); (G.F.); (J.B.); (S.W.); (J.F.); (K.P.); (I.B.); (I.K.); (A.W.)
- German Center for Infection Research (DZIF), Partner Site Munich, 80802 Munich, Germany;
| | - Katja Radon
- Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, 80336 Munich, Germany; (K.R.); (F.F.)
- Center for International Health (CIH), University Hospital, LMU Munich, 80336 Munich, Germany
- Comprehensive Pneumology Center (CPC) Munich, German Center for Lung Research (DZL), 89337 Munich, Germany
| | - Abhishek Bakuli
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany; (M.P.); (A.B.); (L.O.); (J.M.G.N.); (E.S.); (N.C.); (C.R.); (M.P.); (D.M.); (V.T.); (F.R.); (M.N.D.); (G.F.); (J.B.); (S.W.); (J.F.); (K.P.); (I.B.); (I.K.); (A.W.)
| | - Ronan Le Gleut
- Helmholtz Zentrum München—German Research Center for Environmental Health, Institute of Computational Biology, 85764 Neuherberg, Germany; (R.L.G.); (M.G.); (P.P.); (Y.S.); (T.F.); (J.H.); (C.F.)
- Helmholtz Zentrum München—German Research Center for Environmental Health, Core Facility Statistical Consulting, 85764 Neuherberg, Germany
| | - Laura Olbrich
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany; (M.P.); (A.B.); (L.O.); (J.M.G.N.); (E.S.); (N.C.); (C.R.); (M.P.); (D.M.); (V.T.); (F.R.); (M.N.D.); (G.F.); (J.B.); (S.W.); (J.F.); (K.P.); (I.B.); (I.K.); (A.W.)
- German Center for Infection Research (DZIF), Partner Site Munich, 80802 Munich, Germany;
| | - Jessica Michelle Guggenbüehl Noller
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany; (M.P.); (A.B.); (L.O.); (J.M.G.N.); (E.S.); (N.C.); (C.R.); (M.P.); (D.M.); (V.T.); (F.R.); (M.N.D.); (G.F.); (J.B.); (S.W.); (J.F.); (K.P.); (I.B.); (I.K.); (A.W.)
| | - Elmar Saathoff
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany; (M.P.); (A.B.); (L.O.); (J.M.G.N.); (E.S.); (N.C.); (C.R.); (M.P.); (D.M.); (V.T.); (F.R.); (M.N.D.); (G.F.); (J.B.); (S.W.); (J.F.); (K.P.); (I.B.); (I.K.); (A.W.)
- German Center for Infection Research (DZIF), Partner Site Munich, 80802 Munich, Germany;
| | - Noemi Castelletti
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany; (M.P.); (A.B.); (L.O.); (J.M.G.N.); (E.S.); (N.C.); (C.R.); (M.P.); (D.M.); (V.T.); (F.R.); (M.N.D.); (G.F.); (J.B.); (S.W.); (J.F.); (K.P.); (I.B.); (I.K.); (A.W.)
| | - Mercè Garí
- Helmholtz Zentrum München—German Research Center for Environmental Health, Institute of Computational Biology, 85764 Neuherberg, Germany; (R.L.G.); (M.G.); (P.P.); (Y.S.); (T.F.); (J.H.); (C.F.)
| | - Peter Pütz
- Helmholtz Zentrum München—German Research Center for Environmental Health, Institute of Computational Biology, 85764 Neuherberg, Germany; (R.L.G.); (M.G.); (P.P.); (Y.S.); (T.F.); (J.H.); (C.F.)
- Faculty of Business Administration and Economics, Bielefeld University, 33615 Bielefeld, Germany
| | - Yannik Schälte
- Helmholtz Zentrum München—German Research Center for Environmental Health, Institute of Computational Biology, 85764 Neuherberg, Germany; (R.L.G.); (M.G.); (P.P.); (Y.S.); (T.F.); (J.H.); (C.F.)
- Center for Mathematics, Technische Universität München, 85748 Garching, Germany
| | - Turid Frahnow
- Helmholtz Zentrum München—German Research Center for Environmental Health, Institute of Computational Biology, 85764 Neuherberg, Germany; (R.L.G.); (M.G.); (P.P.); (Y.S.); (T.F.); (J.H.); (C.F.)
- Faculty of Business Administration and Economics, Bielefeld University, 33615 Bielefeld, Germany
| | - Roman Wölfel
- German Center for Infection Research (DZIF), Partner Site Munich, 80802 Munich, Germany;
- Bundeswehr Institute of Microbiology, 80937 Munich, Germany
| | - Camilla Rothe
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany; (M.P.); (A.B.); (L.O.); (J.M.G.N.); (E.S.); (N.C.); (C.R.); (M.P.); (D.M.); (V.T.); (F.R.); (M.N.D.); (G.F.); (J.B.); (S.W.); (J.F.); (K.P.); (I.B.); (I.K.); (A.W.)
| | - Michel Pletschette
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany; (M.P.); (A.B.); (L.O.); (J.M.G.N.); (E.S.); (N.C.); (C.R.); (M.P.); (D.M.); (V.T.); (F.R.); (M.N.D.); (G.F.); (J.B.); (S.W.); (J.F.); (K.P.); (I.B.); (I.K.); (A.W.)
| | - Dafni Metaxa
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany; (M.P.); (A.B.); (L.O.); (J.M.G.N.); (E.S.); (N.C.); (C.R.); (M.P.); (D.M.); (V.T.); (F.R.); (M.N.D.); (G.F.); (J.B.); (S.W.); (J.F.); (K.P.); (I.B.); (I.K.); (A.W.)
| | - Felix Forster
- Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital, LMU Munich, 80336 Munich, Germany; (K.R.); (F.F.)
- Comprehensive Pneumology Center (CPC) Munich, German Center for Lung Research (DZL), 89337 Munich, Germany
| | - Verena Thiel
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany; (M.P.); (A.B.); (L.O.); (J.M.G.N.); (E.S.); (N.C.); (C.R.); (M.P.); (D.M.); (V.T.); (F.R.); (M.N.D.); (G.F.); (J.B.); (S.W.); (J.F.); (K.P.); (I.B.); (I.K.); (A.W.)
| | - Friedrich Rieß
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany; (M.P.); (A.B.); (L.O.); (J.M.G.N.); (E.S.); (N.C.); (C.R.); (M.P.); (D.M.); (V.T.); (F.R.); (M.N.D.); (G.F.); (J.B.); (S.W.); (J.F.); (K.P.); (I.B.); (I.K.); (A.W.)
- German Center for Infection Research (DZIF), Partner Site Munich, 80802 Munich, Germany;
| | - Maximilian Nikolaus Diefenbach
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany; (M.P.); (A.B.); (L.O.); (J.M.G.N.); (E.S.); (N.C.); (C.R.); (M.P.); (D.M.); (V.T.); (F.R.); (M.N.D.); (G.F.); (J.B.); (S.W.); (J.F.); (K.P.); (I.B.); (I.K.); (A.W.)
| | - Günter Fröschl
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany; (M.P.); (A.B.); (L.O.); (J.M.G.N.); (E.S.); (N.C.); (C.R.); (M.P.); (D.M.); (V.T.); (F.R.); (M.N.D.); (G.F.); (J.B.); (S.W.); (J.F.); (K.P.); (I.B.); (I.K.); (A.W.)
- Center for International Health (CIH), University Hospital, LMU Munich, 80336 Munich, Germany
| | - Jan Bruger
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany; (M.P.); (A.B.); (L.O.); (J.M.G.N.); (E.S.); (N.C.); (C.R.); (M.P.); (D.M.); (V.T.); (F.R.); (M.N.D.); (G.F.); (J.B.); (S.W.); (J.F.); (K.P.); (I.B.); (I.K.); (A.W.)
| | - Simon Winter
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany; (M.P.); (A.B.); (L.O.); (J.M.G.N.); (E.S.); (N.C.); (C.R.); (M.P.); (D.M.); (V.T.); (F.R.); (M.N.D.); (G.F.); (J.B.); (S.W.); (J.F.); (K.P.); (I.B.); (I.K.); (A.W.)
| | - Jonathan Frese
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany; (M.P.); (A.B.); (L.O.); (J.M.G.N.); (E.S.); (N.C.); (C.R.); (M.P.); (D.M.); (V.T.); (F.R.); (M.N.D.); (G.F.); (J.B.); (S.W.); (J.F.); (K.P.); (I.B.); (I.K.); (A.W.)
| | - Kerstin Puchinger
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany; (M.P.); (A.B.); (L.O.); (J.M.G.N.); (E.S.); (N.C.); (C.R.); (M.P.); (D.M.); (V.T.); (F.R.); (M.N.D.); (G.F.); (J.B.); (S.W.); (J.F.); (K.P.); (I.B.); (I.K.); (A.W.)
| | - Isabel Brand
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany; (M.P.); (A.B.); (L.O.); (J.M.G.N.); (E.S.); (N.C.); (C.R.); (M.P.); (D.M.); (V.T.); (F.R.); (M.N.D.); (G.F.); (J.B.); (S.W.); (J.F.); (K.P.); (I.B.); (I.K.); (A.W.)
| | - Inge Kroidl
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany; (M.P.); (A.B.); (L.O.); (J.M.G.N.); (E.S.); (N.C.); (C.R.); (M.P.); (D.M.); (V.T.); (F.R.); (M.N.D.); (G.F.); (J.B.); (S.W.); (J.F.); (K.P.); (I.B.); (I.K.); (A.W.)
- German Center for Infection Research (DZIF), Partner Site Munich, 80802 Munich, Germany;
| | - Jan Hasenauer
- Helmholtz Zentrum München—German Research Center for Environmental Health, Institute of Computational Biology, 85764 Neuherberg, Germany; (R.L.G.); (M.G.); (P.P.); (Y.S.); (T.F.); (J.H.); (C.F.)
- Center for Mathematics, Technische Universität München, 85748 Garching, Germany
- Interdisciplinary Research Unit Mathematics and Life Sciences, University of Bonn, 53113 Bonn, Germany
| | - Christiane Fuchs
- Helmholtz Zentrum München—German Research Center for Environmental Health, Institute of Computational Biology, 85764 Neuherberg, Germany; (R.L.G.); (M.G.); (P.P.); (Y.S.); (T.F.); (J.H.); (C.F.)
- Helmholtz Zentrum München—German Research Center for Environmental Health, Core Facility Statistical Consulting, 85764 Neuherberg, Germany
- Faculty of Business Administration and Economics, Bielefeld University, 33615 Bielefeld, Germany
- Center for Mathematics, Technische Universität München, 85748 Garching, Germany
| | - Andreas Wieser
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany; (M.P.); (A.B.); (L.O.); (J.M.G.N.); (E.S.); (N.C.); (C.R.); (M.P.); (D.M.); (V.T.); (F.R.); (M.N.D.); (G.F.); (J.B.); (S.W.); (J.F.); (K.P.); (I.B.); (I.K.); (A.W.)
- German Center for Infection Research (DZIF), Partner Site Munich, 80802 Munich, Germany;
| | - Michael Hoelscher
- Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, 80802 Munich, Germany; (M.P.); (A.B.); (L.O.); (J.M.G.N.); (E.S.); (N.C.); (C.R.); (M.P.); (D.M.); (V.T.); (F.R.); (M.N.D.); (G.F.); (J.B.); (S.W.); (J.F.); (K.P.); (I.B.); (I.K.); (A.W.)
- German Center for Infection Research (DZIF), Partner Site Munich, 80802 Munich, Germany;
- Center for International Health (CIH), University Hospital, LMU Munich, 80336 Munich, Germany
- Correspondence: ; Tel.: +49-89-44005-9801
| | | |
Collapse
|
21
|
Abstract
BACKGROUND Tissues are often heterogeneous in their single-cell molecular expression, and this can govern the regulation of cell fate. For the understanding of development and disease, it is important to quantify heterogeneity in a given tissue. RESULTS We present the R package stochprofML which uses the maximum likelihood principle to parameterize heterogeneity from the cumulative expression of small random pools of cells. We evaluate the algorithm's performance in simulation studies and present further application opportunities. CONCLUSION Stochastic profiling outweighs the necessary demixing of mixed samples with a saving in experimental cost and effort and less measurement error. It offers possibilities for parameterizing heterogeneity, estimating underlying pool compositions and detecting differences between cell populations between samples.
Collapse
Affiliation(s)
- Lisa Amrhein
- Institute of Computational Biology, Helmholtz Zentrum München, Ingolstädter Landstrasse 1, 85764 Neuherberg, Germany
- Department of Mathematics, Technical University Munich, Boltzmannstrasse 3, 85748 Garching, Germany
| | - Christiane Fuchs
- Institute of Computational Biology, Helmholtz Zentrum München, Ingolstädter Landstrasse 1, 85764 Neuherberg, Germany
- Department of Mathematics, Technical University Munich, Boltzmannstrasse 3, 85748 Garching, Germany
- Faculty of Business Administration and Economics, Bielefeld University, Universitätsstrasse 25, 33615 Bielefeld, Germany
| |
Collapse
|
22
|
Krautenbacher N, Kabesch M, Horak E, Braun-Fahrländer C, Genuneit J, Boznanski A, von Mutius E, Theis F, Fuchs C, Ege MJ. Asthma in farm children is more determined by genetic polymorphisms and in non-farm children by environmental factors. Pediatr Allergy Immunol 2021; 32:295-304. [PMID: 32997854 DOI: 10.1111/pai.13385] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/27/2020] [Revised: 09/22/2020] [Accepted: 09/23/2020] [Indexed: 01/06/2023]
Abstract
BACKGROUND The asthma syndrome is influenced by hereditary and environmental factors. With the example of farm exposure, we study whether genetic and environmental factors interact for asthma. METHODS Statistical learning approaches based on penalized regression and decision trees were used to predict asthma in the GABRIELA study with 850 cases (9% farm children) and 857 controls (14% farm children). Single-nucleotide polymorphisms (SNPs) were selected from a genome-wide dataset based on a literature search or by statistical selection techniques. Prediction was assessed by receiver operating characteristics (ROC) curves and validated in the PASTURE cohort. RESULTS Prediction by family history of asthma and atopy yielded an area under the ROC curve (AUC) of 0.62 [0.57-0.66] in the random forest machine learning approach. By adding information on demographics (sex and age) and 26 environmental exposure variables, the quality of prediction significantly improved (AUC = 0.65 [0.61-0.70]). In farm children, however, environmental variables did not improve prediction quality. Rather SNPs related to IL33 and RAD50 contributed significantly to the prediction of asthma (AUC = 0.70 [0.62-0.78]). CONCLUSIONS Asthma in farm children is more likely predicted by other factors as compared to non-farm children though in both forms, family history may integrate environmental exposure, genotype and degree of penetrance.
Collapse
Affiliation(s)
- Norbert Krautenbacher
- Helmholtz Zentrum München, German Research Center for Environmental Health, Institute of Computational Biology, Neuherberg, Germany.,Center for Mathematics, Chair of Mathematical Modeling of Biological Systems, Technische Universität München, Garching, Germany
| | - Michael Kabesch
- University Children's Hospital Regensburg (KUNO), Regensburg, Germany.,Clinic for Pediatric Pneumology and Neonatology, Hannover Medical School, Hannover, Germany.,The German Center for Lung Research (DZL), Germany
| | - Elisabeth Horak
- Department of Pediatrics and Adolescents, Innsbruck Medical University, Innsbruck, Austria
| | - Charlotte Braun-Fahrländer
- Swiss Tropical and Public Health Institute Basel, Basel, Switzerland.,University of Basel, Basel, Switzerland
| | - Jon Genuneit
- Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany.,Pediatric Epidemiology, Department of Pediatrics, Medical Faculty, Leipzig University, Leipzig, Germany
| | | | - Erika von Mutius
- The German Center for Lung Research (DZL), Germany.,Dr von Hauner Children's Hospital, LMU Munich, Munich, Germany.,Helmholtz Zentrum München, German Research Center for Environmental Health, Institute of Asthma and Allergy Prevention, Neuherberg, Germany
| | - Fabian Theis
- Helmholtz Zentrum München, German Research Center for Environmental Health, Institute of Computational Biology, Neuherberg, Germany.,Center for Mathematics, Chair of Mathematical Modeling of Biological Systems, Technische Universität München, Garching, Germany
| | - Christiane Fuchs
- Helmholtz Zentrum München, German Research Center for Environmental Health, Institute of Computational Biology, Neuherberg, Germany.,Center for Mathematics, Chair of Mathematical Modeling of Biological Systems, Technische Universität München, Garching, Germany.,Department of Business Administration and Economics, Bielefeld University, Bielefeld, Germany
| | - Markus J Ege
- The German Center for Lung Research (DZL), Germany.,Dr von Hauner Children's Hospital, LMU Munich, Munich, Germany
| | | |
Collapse
|
23
|
Abstract
AbstractThe analysis of single-cell RNA sequencing data is of great importance in health research. It challenges data scientists, but has enormous potential in the context of personalized medicine. The clustering of single cells aims to detect different subgroups of cell populations within a patient in a data-driven manner. Some comparison studies denote single-cell consensus clustering (SC3), proposed by Kiselev et al. (Nat Methods 14(5):483–486, 2017), as the best method for classifying single-cell RNA sequencing data. SC3 includes Laplacian eigenmaps and a principal component analysis (PCA). Our proposal of unsupervised adapted single-cell consensus clustering (adaSC3) suggests to replace the linear PCA by diffusion maps, a non-linear method that takes the transition of single cells into account. We investigate the performance of adaSC3 in terms of accuracy on the data sets of the original source of SC3 as well as in a simulation study. A comparison of adaSC3 with SC3 as well as with related algorithms based on further alternative dimension reduction techniques shows a quite convincing behavior of adaSC3.
Collapse
|
24
|
Pieschner S, Fuchs C. Bayesian inference for diffusion processes: using higher-order approximations for transition densities. R Soc Open Sci 2020; 7:200270. [PMID: 33204444 PMCID: PMC7657901 DOI: 10.1098/rsos.200270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 02/19/2020] [Accepted: 09/17/2020] [Indexed: 06/11/2023]
Abstract
Modelling random dynamical systems in continuous time, diffusion processes are a powerful tool in many areas of science. Model parameters can be estimated from time-discretely observed processes using Markov chain Monte Carlo (MCMC) methods that introduce auxiliary data. These methods typically approximate the transition densities of the process numerically, both for calculating the posterior densities and proposing auxiliary data. Here, the Euler-Maruyama scheme is the standard approximation technique. However, the MCMC method is computationally expensive. Using higher-order approximations may accelerate it, but the specific implementation and benefit remain unclear. Hence, we investigate the utilization and usefulness of higher-order approximations in the example of the Milstein scheme. Our study demonstrates that the MCMC methods based on the Milstein approximation yield good estimation results. However, they are computationally more expensive and can be applied to multidimensional processes only with impractical restrictions. Moreover, the combination of the Milstein approximation and the well-known modified bridge proposal introduces additional numerical challenges.
Collapse
Affiliation(s)
- Susanne Pieschner
- Institute of Computational Biology, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstädter Landstr. 1, 85764 Neuherberg, Germany
- Department of Mathematics, Technische Universität München, Boltzmannstrasse 3, 85748 Garching, Germany
| | - Christiane Fuchs
- Institute of Computational Biology, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstädter Landstr. 1, 85764 Neuherberg, Germany
- Department of Mathematics, Technische Universität München, Boltzmannstrasse 3, 85748 Garching, Germany
- Data Science Group, Faculty of Business Administration and Economics, Universität Bielefeld, Postfach 100131, 33501 Bielefeld, Germany
| |
Collapse
|
25
|
Armstrong V, Buschmann U, Ebert R, Fuchs C, Rieger J, Scheler F. Biochemical investigations of CAPD: Plasma levels of trace elements and amino acids and impaired glucose tolerance during the course of treatment. Int J Artif Organs 2020. [DOI: 10.1177/039139888000300412] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Investigations have been initiated into the effect of CAPD on the plasma concentrations of trace elements and amino acids, and in particular the response of patients to an oral glucose tolerance test (OGTT) during the course of treatment. Six months CAPD had no effect on the plasma concentrations of aluminium, fluoride, zinc and copper. Levels of aluminium and fluoride were above the normal range. Loss of amino acids in the dialysate correlated with their plasma concentrations. No changes were observed in the E/NE, Val/Gly or Tyr/Phe ratios during nine months treatment. Five CAPD patients demonstrated an impaired glucose tolerance in response to an OGTT after one month of treatment and a further deterioration occurred in the glucose tolerance of three patients after another six months CAPD. In a preliminary investigation with fructose substituted for glucose in the dialysate of one patient, an improvement in the OGTT and rate of insulin secretion was observed after 3 days dialysis against fructose.
Collapse
Affiliation(s)
- V.W. Armstrong
- University Medical Clinic Göttingen, Federal Republic of Germany
| | - U. Buschmann
- University Medical Clinic Göttingen, Federal Republic of Germany
| | - R. Ebert
- University Medical Clinic Göttingen, Federal Republic of Germany
| | - C. Fuchs
- University Medical Clinic Göttingen, Federal Republic of Germany
| | - J. Rieger
- University Medical Clinic Göttingen, Federal Republic of Germany
| | - F. Scheler
- University Medical Clinic Göttingen, Federal Republic of Germany
| |
Collapse
|
26
|
Becker M, Noll-Puchta H, Amend D, Nolte F, Fuchs C, Jeremias I, Braun CJ. CLUE: a bioinformatic and wet-lab pipeline for multiplexed cloning of custom sgRNA libraries. Nucleic Acids Res 2020; 48:e78. [PMID: 32479629 PMCID: PMC7367185 DOI: 10.1093/nar/gkaa459] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2020] [Revised: 05/09/2020] [Accepted: 05/18/2020] [Indexed: 12/12/2022] Open
Abstract
The systematic perturbation of genomes using CRISPR/Cas9 deciphers gene function at an unprecedented rate, depth and ease. Commercially available sgRNA libraries typically contain tens of thousands of pre-defined constructs, resulting in a complexity challenging to handle. In contrast, custom sgRNA libraries comprise gene sets of self-defined content and size, facilitating experiments under complex conditions such as in vivo systems. To streamline and upscale cloning of custom libraries, we present CLUE, a bioinformatic and wet-lab pipeline for the multiplexed generation of pooled sgRNA libraries. CLUE starts from lists of genes or pasted sequences provided by the user and designs a single synthetic oligonucleotide pool containing various libraries. At the core of the approach, a barcoding strategy for unique primer binding sites allows amplifying different user-defined libraries from one single oligonucleotide pool. We prove the approach to be straightforward, versatile and specific, yielding uniform sgRNA distributions in all resulting libraries, virtually devoid of cross-contaminations. For in silico library multiplexing and design, we established an easy-to-use online platform at www.crispr-clue.de. All in all, CLUE represents a resource-saving approach to produce numerous high quality custom sgRNA libraries in parallel, which will foster their broad use across molecular biosciences.
Collapse
Affiliation(s)
- Martin Becker
- Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Center for Environmental Health (HMGU), 81377 Munich, Germany
| | - Heidi Noll-Puchta
- Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig Maximilians University of Munich (LMU), 80337 Munich, Germany
| | - Diana Amend
- Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Center for Environmental Health (HMGU), 81377 Munich, Germany
| | - Florian Nolte
- Faculty of Business Administration and Economics, Bielefeld University, Bielefeld, Germany
| | - Christiane Fuchs
- Faculty of Business Administration and Economics, Bielefeld University, Bielefeld, Germany
- Department of Mathematics, Technische Universität München, Munich, Germany
- Helmholtz Zentrum München - German Research Center for Environmental Health, Institute of Computational Biology, Munich, Neuherberg, Germany
| | - Irmela Jeremias
- Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Center for Environmental Health (HMGU), 81377 Munich, Germany
- Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig Maximilians University of Munich (LMU), 80337 Munich, Germany
- German Consortium for Translational Cancer Research (DKTK), Partnering Site Munich, 80336 Munich, Germany
| | - Christian J Braun
- Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig Maximilians University of Munich (LMU), 80337 Munich, Germany
- Institute of Molecular Oncology and Functional Genomics, TUM School of Medicine, Technische Universität München, Munich, Germany
- Hopp Children's Cancer Center Heidelberg (KiTZ), German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany
| |
Collapse
|
27
|
Yoon H, Fuchs C, Özgüroğlu M, Bang Y, Bartolomeo MD, Mandala M, Ryu M, Fornaro L, Olesinski T, Caglevic C, Chung H, Muro K, Cutsem EV, Elme A, Thuss-Patience P, Chau I, Ohtsu A, Wang A, Bhagia P, Lin J, Shih C, Shitara K. O-12 KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.065] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
28
|
Tabernero J, Bang Y, Cutsem EV, Fuchs C, Janjigian Y, Bhagia P, Li K, Adelberg D, Qin S. P-38 KEYNOTE-859: A randomized, double-blind, placebo-controlled phase 3 trial of first-line pembrolizumab plus chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.120] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
29
|
Hibbah EH, El Maroufy H, Fuchs C, Ziad T. An MCMC computational approach for a continuous time state-dependent regime switching diffusion process. J Appl Stat 2020; 47:1354-1374. [DOI: 10.1080/02664763.2019.1677573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- El Houcine Hibbah
- Department of Applied Mathematics, Faculty of Sciences and Technics, Sultan Mouly Slimane University, Morocco
| | - Hamid El Maroufy
- Department of Applied Mathematics, Faculty of Sciences and Technics, Sultan Mouly Slimane University, Morocco
| | - Christiane Fuchs
- Faculty of Business Administration and Economics, Bielefeld University, Bielefield, Germany
- Helmholtz Zentrum Munchen, German Research Center for Environmental Health GmbH, Institute of Computational Biology, Neuherberg, Germany
- Chair of Mathematical Modeling of Biology Systems, Technisché Universität München, Garching, Germany
| | - Taib Ziad
- Faculty of Mathematics, Chalmers University of Technology, Göteborg, Sweden
- Statistical Science Director at Astrazeneca, Sweden
| |
Collapse
|
30
|
Trovò L, Fuchs C, De Rosa R, Barbiero I, Tramarin M, Ciani E, Rusconi L, Kilstrup-Nielsen C. The green tea polyphenol epigallocatechin-3-gallate (EGCG) restores CDKL5-dependent synaptic defects in vitro and in vivo. Neurobiol Dis 2020; 138:104791. [PMID: 32032735 PMCID: PMC7152796 DOI: 10.1016/j.nbd.2020.104791] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2019] [Revised: 01/23/2020] [Accepted: 02/03/2020] [Indexed: 01/30/2023] Open
Abstract
CDKL5 deficiency disorder (CDD) is a rare X-linked neurodevelopmental disorder that is characterised by early-onset seizures, intellectual disability, gross motor impairment, and autistic-like features. CDD is caused by mutations in the cyclin-dependent kinase-like 5 (CDKL5) gene that encodes a serine/threonine kinase with a predominant expression in the brain. Loss of CDKL5 causes neurodevelopmental alterations in vitro and in vivo, including defective dendritic arborisation and spine maturation, which most likely underlie the cognitive defects and autistic features present in humans and mice. Here, we show that treatment with epigallatocathechin-3-gallate (EGCG), the major polyphenol of green tea, can restore defects in dendritic and synaptic development of primary Cdkl5 knockout (KO) neurons. Furthermore, defective synaptic maturation in the hippocampi and cortices of adult Cdkl5-KO mice can be rescued through the intraperitoneal administration of EGCG, which is however not sufficient to normalise behavioural CDKL5-dependent deficits. EGCG is a pleiotropic compound with numerous cellular targets, including the dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) that is selectively inhibited by EGCG. DYRK1A controls dendritic development and spine formation and its deregulation has been implicated in neurodevelopmental and degenerative diseases. Treatment with another DYRK1A inhibitor, harmine, was capable of correcting neuronal CDKL5-dependent defects; moreover, DYRK1A levels were upregulated in primary Cdkl5-KO neurons in concomitance with increased phosphorylation of Tau, a well-accepted DYRK1A substrate. Altogether, our results indicate that DYRK1A deregulation may contribute, at least in part, to the neurodevelopmental alterations caused by CDKL5 deficiency.
Collapse
Affiliation(s)
- L Trovò
- Center of Neuroscience, Dept. Biotechnology and Life Sciences (DBSV), University of Insubria, Varese, Italy
| | - C Fuchs
- Dept. Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy; Center of Neuroscience, Dept. Biotechnology and Life Sciences (DBSV), University of Insubria, Varese, Italy
| | - R De Rosa
- Center of Neuroscience, Dept. Biotechnology and Life Sciences (DBSV), University of Insubria, Varese, Italy
| | - I Barbiero
- Center of Neuroscience, Dept. Biotechnology and Life Sciences (DBSV), University of Insubria, Varese, Italy
| | - M Tramarin
- Center of Neuroscience, Dept. Biotechnology and Life Sciences (DBSV), University of Insubria, Varese, Italy
| | - E Ciani
- Dept. Biomedical and NeuroMotor Sciences, University of Bologna, Bologna, Italy
| | - L Rusconi
- Center of Neuroscience, Dept. Biotechnology and Life Sciences (DBSV), University of Insubria, Varese, Italy
| | - C Kilstrup-Nielsen
- Center of Neuroscience, Dept. Biotechnology and Life Sciences (DBSV), University of Insubria, Varese, Italy.
| |
Collapse
|
31
|
Normann N, Tietz G, Kühn A, Fuchs C, Balau V, Schulz K, Kolata J, Schuerholz T, Petersmann A, Stentzel S, Steil L, Kuhn SO, Meissner K, Völker U, Nauck M, Steinmetz I, Raafat D, Gründling M, Bröker BM. Pathogen-specific antibody profiles in patients with severe systemic infections. Eur Cell Mater 2020; 39:171-182. [PMID: 32301500 DOI: 10.22203/ecm.v039a11] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
Infections are often caused by pathobionts, endogenous bacteria that belong to the microbiota. Trauma and surgical intervention can allow bacteria to overcome host defences, ultimately leading to sepsis if left untreated. One of the main defence strategies of the immune system is the production of highly specific antibodies. In the present proof-of-concept study, plasma antibodies against 9 major pathogens were measured in sepsis patients, as an example of severe systemic infections. The binding of plasma antibodies to bacterial extracellular proteins was quantified using a semi-automated immunoblot assay. Comparison of the pathogen-specific antibody levels before and after infection showed an increase in plasma IgG in 20 out of 37 tested patients. This host-directed approach extended the results of pathogen-oriented microbiological and PCR diagnostics: a specific antibody response to additional bacteria was frequently observed, indicating unrecognised poly-microbial invasion. This might explain some cases of failed, seemingly targeted antibiotic treatment.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - B M Bröker
- Department of Immunology, University Medicine Greifswald, Greifswald,
| |
Collapse
|
32
|
Tam J, Purschke M, Fuchs C, Wang Y, Anderson RR. Skin Microcolumns as a Source of Paracrine Signaling Factors. Adv Wound Care (New Rochelle) 2020; 9:174-183. [PMID: 32117581 PMCID: PMC7047113 DOI: 10.1089/wound.2019.1045] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2019] [Accepted: 09/17/2019] [Indexed: 01/08/2023] Open
Abstract
Objective: We recently developed the approach of using “microcolumns” of autologous full-thickness skin tissue for wound repair. The small size of these micro skin tissue columns (MSTCs, ∼0.5 mm in diameter) allows donor sites to heal quickly without scarring. Treatment with MSTCs significantly accelerate wound healing, and suppled various skin cell types and skin structures to replenish the wound volume. This technology is now starting clinical use. In this study, we investigate whether MSTCs may also influence wound healing by releasing soluble signaling factors. Approach: Freshly harvested MSTCs were incubated in culture medium for 24 h. The conditioned medium was collected and tested for its effects on migration and proliferation of human dermal fibroblasts, and its ability to induce tube formation by human umbilical vein endothelial cells (HUVECs). Proteins released into the conditioned medium were characterized by multiplex enzyme-linked immunosorbent assay (ELISA), and compared with medium conditioned by an equivalent mass of intact full-thickness skin. Results: MSTC-conditioned medium increased fibroblast migration and proliferation, as well as HUVEC tube formation. MSTCs released many soluble factors known to play prominent roles in wound healing. A subset of proteins showed significantly different release profiles compared with intact full-thickness skin. Innovation: The technology for harvesting and using MSTCs to augment wound healing was recently developed as an alternative to conventional autologous skin grafting. This study shows that MSTCs could also function as “cytokine factories.” Conclusion: In addition to supplying autologous cells to repopulate the wound volume, MSTCs can also function as a source of growth factors and cytokines to further enhance wound healing.
Collapse
Affiliation(s)
- Joshua Tam
- Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts
- Department of Dermatology, Harvard Medical School, Boston, Massachusetts
| | - Martin Purschke
- Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts
- Department of Dermatology, Harvard Medical School, Boston, Massachusetts
| | - Christiane Fuchs
- Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts
- Department of Dermatology, Harvard Medical School, Boston, Massachusetts
| | - Ying Wang
- Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts
- Department of Dermatology, Harvard Medical School, Boston, Massachusetts
| | - R. Rox Anderson
- Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts
- Department of Dermatology, Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
33
|
Leaker BD, Fuchs C, Tam J. When Wounds Are Good for You: The Regenerative Capacity of Fractional Resurfacing and Potential Utility in Chronic Wound Prevention. Adv Wound Care (New Rochelle) 2019; 8:679-691. [PMID: 31750016 DOI: 10.1089/wound.2019.0945] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2019] [Accepted: 04/03/2019] [Indexed: 12/24/2022] Open
Abstract
Significance: Fractional resurfacing involves producing arrays of microinjuries on the skin, by thermal or mechanical means, to trigger tissue regeneration. Originally developed for cosmetic enhancement, fractional resurfacing induces a broad array of improvements in the structural and functional qualities of the treated skin and is especially effective at returning defective skin to a more normal state. In addition to fascinating questions about the nature of this remarkable regenerative capacity, there may be potential utility in ulcer prevention by halting or even reversing the progressive decline in overall skin quality that usually precedes chronic wound development. Recent Advances: Photoaging and scarring are the two skin defects most commonly treated by fractional resurfacing, and the treatment produces profound and long-lasting improvements in skin quality, both clinically and at the cellular/histologic level. Chronic wounds usually occur in skin that is compromised by various pathologic factors, and many of the defects found in this ulcer-prone skin are similar to those that have seen improvements after fractional resurfacing. Critical Issues: The mechanisms responsible for the regenerative capacity of fractional resurfacing are mostly unknown, as is how ulcer-prone skin, which is usually afflicted by stressors external to the skin tissue itself, would respond to fractional resurfacing. Future Directions: Better understanding of the cellular and molecular mechanisms underlying the unique healing response to fractional resurfacing could reveal fundamental information about adult tissue regeneration, lead to improvements in current applications, as well as new therapies in other pathologic conditions.
Collapse
Affiliation(s)
- Ben D. Leaker
- Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts
- The Harvard-MIT Program in Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts
| | - Christiane Fuchs
- Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts
- Department of Dermatology, Harvard Medical School, Boston, Massachusetts
| | - Joshua Tam
- Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts
- Department of Dermatology, Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
34
|
Van Cutsem E, Valderrama A, Bang YJ, Fuchs C, Shitara K, Janjigian Y, Qin S, Larson T, Shankaran V, Stein S, Norquist J, Kher U, Shah S, Alsina M. Health-related quality of life (HRQoL) impact of pembrolizumab (P) versus chemotherapy (C) as first-line (1L) treatment in PD-L1–positive advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz394.036] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Seyednasrollah F, Koestler DC, Wang T, Piccolo SR, Vega R, Greiner R, Fuchs C, Gofer E, Kumar L, Wolfinger RD, Kanigel Winner K, Bare C, Neto EC, Yu T, Shen L, Abdallah K, Norman T, Stolovitzky G, Soule HR, Sweeney CJ, Ryan CJ, Scher HI, Sartor O, Elo LL, Zhou FL, Guinney J, Costello JC. A DREAM Challenge to Build Prediction Models for Short-Term Discontinuation of Docetaxel in Metastatic Castration-Resistant Prostate Cancer. JCO Clin Cancer Inform 2019; 1:1-15. [PMID: 30657384 PMCID: PMC6874023 DOI: 10.1200/cci.17.00018] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Purpose Docetaxel has a demonstrated survival benefit for patients with metastatic castration-resistant prostate cancer (mCRPC); however, 10% to 20% of patients discontinue docetaxel prematurely because of toxicity-induced adverse events, and the management of risk factors for toxicity remains a challenge. Patients and Methods The comparator arms of four phase III clinical trials in first-line mCRPC were collected, annotated, and compiled, with a total of 2,070 patients. Early discontinuation was defined as treatment stoppage within 3 months as a result of adverse treatment effects; 10% of patients discontinued treatment. We designed an open-data, crowd-sourced DREAM Challenge for developing models with which to predict early discontinuation of docetaxel treatment. Clinical features for all four trials and outcomes for three of the four trials were made publicly available, with the outcomes of the fourth trial held back for unbiased model evaluation. Challenge participants from around the world trained models and submitted their predictions. Area under the precision-recall curve was the primary metric used for performance assessment. Results In total, 34 separate teams submitted predictions. Seven models with statistically similar area under precision-recall curves (Bayes factor ≤ 3) outperformed all other models. A postchallenge analysis of risk prediction using these seven models revealed three patient subgroups: high risk, low risk, or discordant risk. Early discontinuation events were two times higher in the high-risk subgroup compared with the low-risk subgroup. Simulation studies demonstrated that use of patient discontinuation prediction models could reduce patient enrollment in clinical trials without the loss of statistical power. Conclusion This work represents a successful collaboration between 34 international teams that leveraged open clinical trial data. Our results demonstrate that routinely collected clinical features can be used to identify patients with mCRPC who are likely to discontinue treatment because of adverse events and establishes a robust benchmark with implications for clinical trial design.
Collapse
Affiliation(s)
- Fatemeh Seyednasrollah
- Fatemeh Seyednasrollah and Laura L. Elo, Turku Centre for Biotechnology; University of Turku; Åbo Akademi University, Turku, Finland; Devin C. Koestler, University of Kansas Medical Center, Kansas City, KS; Tao Wang, University of Texas Southwestern Medical Center, Dallas, TX; Stephen R. Piccolo, Brigham Young University, Provo; University of Utah, Salt Lake City, Utah, UT; Roberto Vega, Russell Greiner, and Luke Kumar, University of Alberta; Alberta Innovates Centre for Machine Learning, Edmonton, Alberta, Canada; Christiane Fuchs, Helmholtz Zentrum München, Neuherberg; Technische Universität München, Garching, Germany; Eyal Gofer, The Hebrew University, Jerusalem, Israel; Russell D. Wolfinger, SAS Institute, Cary, NC; Kimberly Kanigel Winner and James C. Costello, University of Colorado, Anschutz Medical Campus, Aurora, CO; Chris Bare, Elias Chaibub Neto, Thomas Yu, Thea Norman, and Justin Guinney, Sage Bionetworks, Seattle, WA; Liji Shen and Fang Liz Zhou, Sanofi, Bridgewater, NJ; Kald Abdallah, AstraZeneca, Gaithersburg, MD; Gustavo Stolovitzky, IBM Research, Yorktown Heights; Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Howard R. Soule, Prostate Cancer Foundation, Santa Monica; Charles J. Ryan, University of California, San Francisco, CA; Christopher J. Sweeney, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Oliver Sartor, Tulane University, New Orleans, LA
| | - Devin C Koestler
- Fatemeh Seyednasrollah and Laura L. Elo, Turku Centre for Biotechnology; University of Turku; Åbo Akademi University, Turku, Finland; Devin C. Koestler, University of Kansas Medical Center, Kansas City, KS; Tao Wang, University of Texas Southwestern Medical Center, Dallas, TX; Stephen R. Piccolo, Brigham Young University, Provo; University of Utah, Salt Lake City, Utah, UT; Roberto Vega, Russell Greiner, and Luke Kumar, University of Alberta; Alberta Innovates Centre for Machine Learning, Edmonton, Alberta, Canada; Christiane Fuchs, Helmholtz Zentrum München, Neuherberg; Technische Universität München, Garching, Germany; Eyal Gofer, The Hebrew University, Jerusalem, Israel; Russell D. Wolfinger, SAS Institute, Cary, NC; Kimberly Kanigel Winner and James C. Costello, University of Colorado, Anschutz Medical Campus, Aurora, CO; Chris Bare, Elias Chaibub Neto, Thomas Yu, Thea Norman, and Justin Guinney, Sage Bionetworks, Seattle, WA; Liji Shen and Fang Liz Zhou, Sanofi, Bridgewater, NJ; Kald Abdallah, AstraZeneca, Gaithersburg, MD; Gustavo Stolovitzky, IBM Research, Yorktown Heights; Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Howard R. Soule, Prostate Cancer Foundation, Santa Monica; Charles J. Ryan, University of California, San Francisco, CA; Christopher J. Sweeney, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Oliver Sartor, Tulane University, New Orleans, LA
| | - Tao Wang
- Fatemeh Seyednasrollah and Laura L. Elo, Turku Centre for Biotechnology; University of Turku; Åbo Akademi University, Turku, Finland; Devin C. Koestler, University of Kansas Medical Center, Kansas City, KS; Tao Wang, University of Texas Southwestern Medical Center, Dallas, TX; Stephen R. Piccolo, Brigham Young University, Provo; University of Utah, Salt Lake City, Utah, UT; Roberto Vega, Russell Greiner, and Luke Kumar, University of Alberta; Alberta Innovates Centre for Machine Learning, Edmonton, Alberta, Canada; Christiane Fuchs, Helmholtz Zentrum München, Neuherberg; Technische Universität München, Garching, Germany; Eyal Gofer, The Hebrew University, Jerusalem, Israel; Russell D. Wolfinger, SAS Institute, Cary, NC; Kimberly Kanigel Winner and James C. Costello, University of Colorado, Anschutz Medical Campus, Aurora, CO; Chris Bare, Elias Chaibub Neto, Thomas Yu, Thea Norman, and Justin Guinney, Sage Bionetworks, Seattle, WA; Liji Shen and Fang Liz Zhou, Sanofi, Bridgewater, NJ; Kald Abdallah, AstraZeneca, Gaithersburg, MD; Gustavo Stolovitzky, IBM Research, Yorktown Heights; Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Howard R. Soule, Prostate Cancer Foundation, Santa Monica; Charles J. Ryan, University of California, San Francisco, CA; Christopher J. Sweeney, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Oliver Sartor, Tulane University, New Orleans, LA
| | - Stephen R Piccolo
- Fatemeh Seyednasrollah and Laura L. Elo, Turku Centre for Biotechnology; University of Turku; Åbo Akademi University, Turku, Finland; Devin C. Koestler, University of Kansas Medical Center, Kansas City, KS; Tao Wang, University of Texas Southwestern Medical Center, Dallas, TX; Stephen R. Piccolo, Brigham Young University, Provo; University of Utah, Salt Lake City, Utah, UT; Roberto Vega, Russell Greiner, and Luke Kumar, University of Alberta; Alberta Innovates Centre for Machine Learning, Edmonton, Alberta, Canada; Christiane Fuchs, Helmholtz Zentrum München, Neuherberg; Technische Universität München, Garching, Germany; Eyal Gofer, The Hebrew University, Jerusalem, Israel; Russell D. Wolfinger, SAS Institute, Cary, NC; Kimberly Kanigel Winner and James C. Costello, University of Colorado, Anschutz Medical Campus, Aurora, CO; Chris Bare, Elias Chaibub Neto, Thomas Yu, Thea Norman, and Justin Guinney, Sage Bionetworks, Seattle, WA; Liji Shen and Fang Liz Zhou, Sanofi, Bridgewater, NJ; Kald Abdallah, AstraZeneca, Gaithersburg, MD; Gustavo Stolovitzky, IBM Research, Yorktown Heights; Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Howard R. Soule, Prostate Cancer Foundation, Santa Monica; Charles J. Ryan, University of California, San Francisco, CA; Christopher J. Sweeney, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Oliver Sartor, Tulane University, New Orleans, LA
| | - Roberto Vega
- Fatemeh Seyednasrollah and Laura L. Elo, Turku Centre for Biotechnology; University of Turku; Åbo Akademi University, Turku, Finland; Devin C. Koestler, University of Kansas Medical Center, Kansas City, KS; Tao Wang, University of Texas Southwestern Medical Center, Dallas, TX; Stephen R. Piccolo, Brigham Young University, Provo; University of Utah, Salt Lake City, Utah, UT; Roberto Vega, Russell Greiner, and Luke Kumar, University of Alberta; Alberta Innovates Centre for Machine Learning, Edmonton, Alberta, Canada; Christiane Fuchs, Helmholtz Zentrum München, Neuherberg; Technische Universität München, Garching, Germany; Eyal Gofer, The Hebrew University, Jerusalem, Israel; Russell D. Wolfinger, SAS Institute, Cary, NC; Kimberly Kanigel Winner and James C. Costello, University of Colorado, Anschutz Medical Campus, Aurora, CO; Chris Bare, Elias Chaibub Neto, Thomas Yu, Thea Norman, and Justin Guinney, Sage Bionetworks, Seattle, WA; Liji Shen and Fang Liz Zhou, Sanofi, Bridgewater, NJ; Kald Abdallah, AstraZeneca, Gaithersburg, MD; Gustavo Stolovitzky, IBM Research, Yorktown Heights; Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Howard R. Soule, Prostate Cancer Foundation, Santa Monica; Charles J. Ryan, University of California, San Francisco, CA; Christopher J. Sweeney, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Oliver Sartor, Tulane University, New Orleans, LA
| | - Russell Greiner
- Fatemeh Seyednasrollah and Laura L. Elo, Turku Centre for Biotechnology; University of Turku; Åbo Akademi University, Turku, Finland; Devin C. Koestler, University of Kansas Medical Center, Kansas City, KS; Tao Wang, University of Texas Southwestern Medical Center, Dallas, TX; Stephen R. Piccolo, Brigham Young University, Provo; University of Utah, Salt Lake City, Utah, UT; Roberto Vega, Russell Greiner, and Luke Kumar, University of Alberta; Alberta Innovates Centre for Machine Learning, Edmonton, Alberta, Canada; Christiane Fuchs, Helmholtz Zentrum München, Neuherberg; Technische Universität München, Garching, Germany; Eyal Gofer, The Hebrew University, Jerusalem, Israel; Russell D. Wolfinger, SAS Institute, Cary, NC; Kimberly Kanigel Winner and James C. Costello, University of Colorado, Anschutz Medical Campus, Aurora, CO; Chris Bare, Elias Chaibub Neto, Thomas Yu, Thea Norman, and Justin Guinney, Sage Bionetworks, Seattle, WA; Liji Shen and Fang Liz Zhou, Sanofi, Bridgewater, NJ; Kald Abdallah, AstraZeneca, Gaithersburg, MD; Gustavo Stolovitzky, IBM Research, Yorktown Heights; Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Howard R. Soule, Prostate Cancer Foundation, Santa Monica; Charles J. Ryan, University of California, San Francisco, CA; Christopher J. Sweeney, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Oliver Sartor, Tulane University, New Orleans, LA
| | - Christiane Fuchs
- Fatemeh Seyednasrollah and Laura L. Elo, Turku Centre for Biotechnology; University of Turku; Åbo Akademi University, Turku, Finland; Devin C. Koestler, University of Kansas Medical Center, Kansas City, KS; Tao Wang, University of Texas Southwestern Medical Center, Dallas, TX; Stephen R. Piccolo, Brigham Young University, Provo; University of Utah, Salt Lake City, Utah, UT; Roberto Vega, Russell Greiner, and Luke Kumar, University of Alberta; Alberta Innovates Centre for Machine Learning, Edmonton, Alberta, Canada; Christiane Fuchs, Helmholtz Zentrum München, Neuherberg; Technische Universität München, Garching, Germany; Eyal Gofer, The Hebrew University, Jerusalem, Israel; Russell D. Wolfinger, SAS Institute, Cary, NC; Kimberly Kanigel Winner and James C. Costello, University of Colorado, Anschutz Medical Campus, Aurora, CO; Chris Bare, Elias Chaibub Neto, Thomas Yu, Thea Norman, and Justin Guinney, Sage Bionetworks, Seattle, WA; Liji Shen and Fang Liz Zhou, Sanofi, Bridgewater, NJ; Kald Abdallah, AstraZeneca, Gaithersburg, MD; Gustavo Stolovitzky, IBM Research, Yorktown Heights; Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Howard R. Soule, Prostate Cancer Foundation, Santa Monica; Charles J. Ryan, University of California, San Francisco, CA; Christopher J. Sweeney, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Oliver Sartor, Tulane University, New Orleans, LA
| | - Eyal Gofer
- Fatemeh Seyednasrollah and Laura L. Elo, Turku Centre for Biotechnology; University of Turku; Åbo Akademi University, Turku, Finland; Devin C. Koestler, University of Kansas Medical Center, Kansas City, KS; Tao Wang, University of Texas Southwestern Medical Center, Dallas, TX; Stephen R. Piccolo, Brigham Young University, Provo; University of Utah, Salt Lake City, Utah, UT; Roberto Vega, Russell Greiner, and Luke Kumar, University of Alberta; Alberta Innovates Centre for Machine Learning, Edmonton, Alberta, Canada; Christiane Fuchs, Helmholtz Zentrum München, Neuherberg; Technische Universität München, Garching, Germany; Eyal Gofer, The Hebrew University, Jerusalem, Israel; Russell D. Wolfinger, SAS Institute, Cary, NC; Kimberly Kanigel Winner and James C. Costello, University of Colorado, Anschutz Medical Campus, Aurora, CO; Chris Bare, Elias Chaibub Neto, Thomas Yu, Thea Norman, and Justin Guinney, Sage Bionetworks, Seattle, WA; Liji Shen and Fang Liz Zhou, Sanofi, Bridgewater, NJ; Kald Abdallah, AstraZeneca, Gaithersburg, MD; Gustavo Stolovitzky, IBM Research, Yorktown Heights; Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Howard R. Soule, Prostate Cancer Foundation, Santa Monica; Charles J. Ryan, University of California, San Francisco, CA; Christopher J. Sweeney, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Oliver Sartor, Tulane University, New Orleans, LA
| | - Luke Kumar
- Fatemeh Seyednasrollah and Laura L. Elo, Turku Centre for Biotechnology; University of Turku; Åbo Akademi University, Turku, Finland; Devin C. Koestler, University of Kansas Medical Center, Kansas City, KS; Tao Wang, University of Texas Southwestern Medical Center, Dallas, TX; Stephen R. Piccolo, Brigham Young University, Provo; University of Utah, Salt Lake City, Utah, UT; Roberto Vega, Russell Greiner, and Luke Kumar, University of Alberta; Alberta Innovates Centre for Machine Learning, Edmonton, Alberta, Canada; Christiane Fuchs, Helmholtz Zentrum München, Neuherberg; Technische Universität München, Garching, Germany; Eyal Gofer, The Hebrew University, Jerusalem, Israel; Russell D. Wolfinger, SAS Institute, Cary, NC; Kimberly Kanigel Winner and James C. Costello, University of Colorado, Anschutz Medical Campus, Aurora, CO; Chris Bare, Elias Chaibub Neto, Thomas Yu, Thea Norman, and Justin Guinney, Sage Bionetworks, Seattle, WA; Liji Shen and Fang Liz Zhou, Sanofi, Bridgewater, NJ; Kald Abdallah, AstraZeneca, Gaithersburg, MD; Gustavo Stolovitzky, IBM Research, Yorktown Heights; Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Howard R. Soule, Prostate Cancer Foundation, Santa Monica; Charles J. Ryan, University of California, San Francisco, CA; Christopher J. Sweeney, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Oliver Sartor, Tulane University, New Orleans, LA
| | - Russell D Wolfinger
- Fatemeh Seyednasrollah and Laura L. Elo, Turku Centre for Biotechnology; University of Turku; Åbo Akademi University, Turku, Finland; Devin C. Koestler, University of Kansas Medical Center, Kansas City, KS; Tao Wang, University of Texas Southwestern Medical Center, Dallas, TX; Stephen R. Piccolo, Brigham Young University, Provo; University of Utah, Salt Lake City, Utah, UT; Roberto Vega, Russell Greiner, and Luke Kumar, University of Alberta; Alberta Innovates Centre for Machine Learning, Edmonton, Alberta, Canada; Christiane Fuchs, Helmholtz Zentrum München, Neuherberg; Technische Universität München, Garching, Germany; Eyal Gofer, The Hebrew University, Jerusalem, Israel; Russell D. Wolfinger, SAS Institute, Cary, NC; Kimberly Kanigel Winner and James C. Costello, University of Colorado, Anschutz Medical Campus, Aurora, CO; Chris Bare, Elias Chaibub Neto, Thomas Yu, Thea Norman, and Justin Guinney, Sage Bionetworks, Seattle, WA; Liji Shen and Fang Liz Zhou, Sanofi, Bridgewater, NJ; Kald Abdallah, AstraZeneca, Gaithersburg, MD; Gustavo Stolovitzky, IBM Research, Yorktown Heights; Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Howard R. Soule, Prostate Cancer Foundation, Santa Monica; Charles J. Ryan, University of California, San Francisco, CA; Christopher J. Sweeney, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Oliver Sartor, Tulane University, New Orleans, LA
| | - Kimberly Kanigel Winner
- Fatemeh Seyednasrollah and Laura L. Elo, Turku Centre for Biotechnology; University of Turku; Åbo Akademi University, Turku, Finland; Devin C. Koestler, University of Kansas Medical Center, Kansas City, KS; Tao Wang, University of Texas Southwestern Medical Center, Dallas, TX; Stephen R. Piccolo, Brigham Young University, Provo; University of Utah, Salt Lake City, Utah, UT; Roberto Vega, Russell Greiner, and Luke Kumar, University of Alberta; Alberta Innovates Centre for Machine Learning, Edmonton, Alberta, Canada; Christiane Fuchs, Helmholtz Zentrum München, Neuherberg; Technische Universität München, Garching, Germany; Eyal Gofer, The Hebrew University, Jerusalem, Israel; Russell D. Wolfinger, SAS Institute, Cary, NC; Kimberly Kanigel Winner and James C. Costello, University of Colorado, Anschutz Medical Campus, Aurora, CO; Chris Bare, Elias Chaibub Neto, Thomas Yu, Thea Norman, and Justin Guinney, Sage Bionetworks, Seattle, WA; Liji Shen and Fang Liz Zhou, Sanofi, Bridgewater, NJ; Kald Abdallah, AstraZeneca, Gaithersburg, MD; Gustavo Stolovitzky, IBM Research, Yorktown Heights; Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Howard R. Soule, Prostate Cancer Foundation, Santa Monica; Charles J. Ryan, University of California, San Francisco, CA; Christopher J. Sweeney, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Oliver Sartor, Tulane University, New Orleans, LA
| | - Chris Bare
- Fatemeh Seyednasrollah and Laura L. Elo, Turku Centre for Biotechnology; University of Turku; Åbo Akademi University, Turku, Finland; Devin C. Koestler, University of Kansas Medical Center, Kansas City, KS; Tao Wang, University of Texas Southwestern Medical Center, Dallas, TX; Stephen R. Piccolo, Brigham Young University, Provo; University of Utah, Salt Lake City, Utah, UT; Roberto Vega, Russell Greiner, and Luke Kumar, University of Alberta; Alberta Innovates Centre for Machine Learning, Edmonton, Alberta, Canada; Christiane Fuchs, Helmholtz Zentrum München, Neuherberg; Technische Universität München, Garching, Germany; Eyal Gofer, The Hebrew University, Jerusalem, Israel; Russell D. Wolfinger, SAS Institute, Cary, NC; Kimberly Kanigel Winner and James C. Costello, University of Colorado, Anschutz Medical Campus, Aurora, CO; Chris Bare, Elias Chaibub Neto, Thomas Yu, Thea Norman, and Justin Guinney, Sage Bionetworks, Seattle, WA; Liji Shen and Fang Liz Zhou, Sanofi, Bridgewater, NJ; Kald Abdallah, AstraZeneca, Gaithersburg, MD; Gustavo Stolovitzky, IBM Research, Yorktown Heights; Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Howard R. Soule, Prostate Cancer Foundation, Santa Monica; Charles J. Ryan, University of California, San Francisco, CA; Christopher J. Sweeney, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Oliver Sartor, Tulane University, New Orleans, LA
| | - Elias Chaibub Neto
- Fatemeh Seyednasrollah and Laura L. Elo, Turku Centre for Biotechnology; University of Turku; Åbo Akademi University, Turku, Finland; Devin C. Koestler, University of Kansas Medical Center, Kansas City, KS; Tao Wang, University of Texas Southwestern Medical Center, Dallas, TX; Stephen R. Piccolo, Brigham Young University, Provo; University of Utah, Salt Lake City, Utah, UT; Roberto Vega, Russell Greiner, and Luke Kumar, University of Alberta; Alberta Innovates Centre for Machine Learning, Edmonton, Alberta, Canada; Christiane Fuchs, Helmholtz Zentrum München, Neuherberg; Technische Universität München, Garching, Germany; Eyal Gofer, The Hebrew University, Jerusalem, Israel; Russell D. Wolfinger, SAS Institute, Cary, NC; Kimberly Kanigel Winner and James C. Costello, University of Colorado, Anschutz Medical Campus, Aurora, CO; Chris Bare, Elias Chaibub Neto, Thomas Yu, Thea Norman, and Justin Guinney, Sage Bionetworks, Seattle, WA; Liji Shen and Fang Liz Zhou, Sanofi, Bridgewater, NJ; Kald Abdallah, AstraZeneca, Gaithersburg, MD; Gustavo Stolovitzky, IBM Research, Yorktown Heights; Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Howard R. Soule, Prostate Cancer Foundation, Santa Monica; Charles J. Ryan, University of California, San Francisco, CA; Christopher J. Sweeney, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Oliver Sartor, Tulane University, New Orleans, LA
| | - Thomas Yu
- Fatemeh Seyednasrollah and Laura L. Elo, Turku Centre for Biotechnology; University of Turku; Åbo Akademi University, Turku, Finland; Devin C. Koestler, University of Kansas Medical Center, Kansas City, KS; Tao Wang, University of Texas Southwestern Medical Center, Dallas, TX; Stephen R. Piccolo, Brigham Young University, Provo; University of Utah, Salt Lake City, Utah, UT; Roberto Vega, Russell Greiner, and Luke Kumar, University of Alberta; Alberta Innovates Centre for Machine Learning, Edmonton, Alberta, Canada; Christiane Fuchs, Helmholtz Zentrum München, Neuherberg; Technische Universität München, Garching, Germany; Eyal Gofer, The Hebrew University, Jerusalem, Israel; Russell D. Wolfinger, SAS Institute, Cary, NC; Kimberly Kanigel Winner and James C. Costello, University of Colorado, Anschutz Medical Campus, Aurora, CO; Chris Bare, Elias Chaibub Neto, Thomas Yu, Thea Norman, and Justin Guinney, Sage Bionetworks, Seattle, WA; Liji Shen and Fang Liz Zhou, Sanofi, Bridgewater, NJ; Kald Abdallah, AstraZeneca, Gaithersburg, MD; Gustavo Stolovitzky, IBM Research, Yorktown Heights; Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Howard R. Soule, Prostate Cancer Foundation, Santa Monica; Charles J. Ryan, University of California, San Francisco, CA; Christopher J. Sweeney, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Oliver Sartor, Tulane University, New Orleans, LA
| | - Liji Shen
- Fatemeh Seyednasrollah and Laura L. Elo, Turku Centre for Biotechnology; University of Turku; Åbo Akademi University, Turku, Finland; Devin C. Koestler, University of Kansas Medical Center, Kansas City, KS; Tao Wang, University of Texas Southwestern Medical Center, Dallas, TX; Stephen R. Piccolo, Brigham Young University, Provo; University of Utah, Salt Lake City, Utah, UT; Roberto Vega, Russell Greiner, and Luke Kumar, University of Alberta; Alberta Innovates Centre for Machine Learning, Edmonton, Alberta, Canada; Christiane Fuchs, Helmholtz Zentrum München, Neuherberg; Technische Universität München, Garching, Germany; Eyal Gofer, The Hebrew University, Jerusalem, Israel; Russell D. Wolfinger, SAS Institute, Cary, NC; Kimberly Kanigel Winner and James C. Costello, University of Colorado, Anschutz Medical Campus, Aurora, CO; Chris Bare, Elias Chaibub Neto, Thomas Yu, Thea Norman, and Justin Guinney, Sage Bionetworks, Seattle, WA; Liji Shen and Fang Liz Zhou, Sanofi, Bridgewater, NJ; Kald Abdallah, AstraZeneca, Gaithersburg, MD; Gustavo Stolovitzky, IBM Research, Yorktown Heights; Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Howard R. Soule, Prostate Cancer Foundation, Santa Monica; Charles J. Ryan, University of California, San Francisco, CA; Christopher J. Sweeney, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Oliver Sartor, Tulane University, New Orleans, LA
| | - Kald Abdallah
- Fatemeh Seyednasrollah and Laura L. Elo, Turku Centre for Biotechnology; University of Turku; Åbo Akademi University, Turku, Finland; Devin C. Koestler, University of Kansas Medical Center, Kansas City, KS; Tao Wang, University of Texas Southwestern Medical Center, Dallas, TX; Stephen R. Piccolo, Brigham Young University, Provo; University of Utah, Salt Lake City, Utah, UT; Roberto Vega, Russell Greiner, and Luke Kumar, University of Alberta; Alberta Innovates Centre for Machine Learning, Edmonton, Alberta, Canada; Christiane Fuchs, Helmholtz Zentrum München, Neuherberg; Technische Universität München, Garching, Germany; Eyal Gofer, The Hebrew University, Jerusalem, Israel; Russell D. Wolfinger, SAS Institute, Cary, NC; Kimberly Kanigel Winner and James C. Costello, University of Colorado, Anschutz Medical Campus, Aurora, CO; Chris Bare, Elias Chaibub Neto, Thomas Yu, Thea Norman, and Justin Guinney, Sage Bionetworks, Seattle, WA; Liji Shen and Fang Liz Zhou, Sanofi, Bridgewater, NJ; Kald Abdallah, AstraZeneca, Gaithersburg, MD; Gustavo Stolovitzky, IBM Research, Yorktown Heights; Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Howard R. Soule, Prostate Cancer Foundation, Santa Monica; Charles J. Ryan, University of California, San Francisco, CA; Christopher J. Sweeney, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Oliver Sartor, Tulane University, New Orleans, LA
| | - Thea Norman
- Fatemeh Seyednasrollah and Laura L. Elo, Turku Centre for Biotechnology; University of Turku; Åbo Akademi University, Turku, Finland; Devin C. Koestler, University of Kansas Medical Center, Kansas City, KS; Tao Wang, University of Texas Southwestern Medical Center, Dallas, TX; Stephen R. Piccolo, Brigham Young University, Provo; University of Utah, Salt Lake City, Utah, UT; Roberto Vega, Russell Greiner, and Luke Kumar, University of Alberta; Alberta Innovates Centre for Machine Learning, Edmonton, Alberta, Canada; Christiane Fuchs, Helmholtz Zentrum München, Neuherberg; Technische Universität München, Garching, Germany; Eyal Gofer, The Hebrew University, Jerusalem, Israel; Russell D. Wolfinger, SAS Institute, Cary, NC; Kimberly Kanigel Winner and James C. Costello, University of Colorado, Anschutz Medical Campus, Aurora, CO; Chris Bare, Elias Chaibub Neto, Thomas Yu, Thea Norman, and Justin Guinney, Sage Bionetworks, Seattle, WA; Liji Shen and Fang Liz Zhou, Sanofi, Bridgewater, NJ; Kald Abdallah, AstraZeneca, Gaithersburg, MD; Gustavo Stolovitzky, IBM Research, Yorktown Heights; Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Howard R. Soule, Prostate Cancer Foundation, Santa Monica; Charles J. Ryan, University of California, San Francisco, CA; Christopher J. Sweeney, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Oliver Sartor, Tulane University, New Orleans, LA
| | - Gustavo Stolovitzky
- Fatemeh Seyednasrollah and Laura L. Elo, Turku Centre for Biotechnology; University of Turku; Åbo Akademi University, Turku, Finland; Devin C. Koestler, University of Kansas Medical Center, Kansas City, KS; Tao Wang, University of Texas Southwestern Medical Center, Dallas, TX; Stephen R. Piccolo, Brigham Young University, Provo; University of Utah, Salt Lake City, Utah, UT; Roberto Vega, Russell Greiner, and Luke Kumar, University of Alberta; Alberta Innovates Centre for Machine Learning, Edmonton, Alberta, Canada; Christiane Fuchs, Helmholtz Zentrum München, Neuherberg; Technische Universität München, Garching, Germany; Eyal Gofer, The Hebrew University, Jerusalem, Israel; Russell D. Wolfinger, SAS Institute, Cary, NC; Kimberly Kanigel Winner and James C. Costello, University of Colorado, Anschutz Medical Campus, Aurora, CO; Chris Bare, Elias Chaibub Neto, Thomas Yu, Thea Norman, and Justin Guinney, Sage Bionetworks, Seattle, WA; Liji Shen and Fang Liz Zhou, Sanofi, Bridgewater, NJ; Kald Abdallah, AstraZeneca, Gaithersburg, MD; Gustavo Stolovitzky, IBM Research, Yorktown Heights; Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Howard R. Soule, Prostate Cancer Foundation, Santa Monica; Charles J. Ryan, University of California, San Francisco, CA; Christopher J. Sweeney, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Oliver Sartor, Tulane University, New Orleans, LA
| | - Howard R Soule
- Fatemeh Seyednasrollah and Laura L. Elo, Turku Centre for Biotechnology; University of Turku; Åbo Akademi University, Turku, Finland; Devin C. Koestler, University of Kansas Medical Center, Kansas City, KS; Tao Wang, University of Texas Southwestern Medical Center, Dallas, TX; Stephen R. Piccolo, Brigham Young University, Provo; University of Utah, Salt Lake City, Utah, UT; Roberto Vega, Russell Greiner, and Luke Kumar, University of Alberta; Alberta Innovates Centre for Machine Learning, Edmonton, Alberta, Canada; Christiane Fuchs, Helmholtz Zentrum München, Neuherberg; Technische Universität München, Garching, Germany; Eyal Gofer, The Hebrew University, Jerusalem, Israel; Russell D. Wolfinger, SAS Institute, Cary, NC; Kimberly Kanigel Winner and James C. Costello, University of Colorado, Anschutz Medical Campus, Aurora, CO; Chris Bare, Elias Chaibub Neto, Thomas Yu, Thea Norman, and Justin Guinney, Sage Bionetworks, Seattle, WA; Liji Shen and Fang Liz Zhou, Sanofi, Bridgewater, NJ; Kald Abdallah, AstraZeneca, Gaithersburg, MD; Gustavo Stolovitzky, IBM Research, Yorktown Heights; Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Howard R. Soule, Prostate Cancer Foundation, Santa Monica; Charles J. Ryan, University of California, San Francisco, CA; Christopher J. Sweeney, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Oliver Sartor, Tulane University, New Orleans, LA
| | - Christopher J Sweeney
- Fatemeh Seyednasrollah and Laura L. Elo, Turku Centre for Biotechnology; University of Turku; Åbo Akademi University, Turku, Finland; Devin C. Koestler, University of Kansas Medical Center, Kansas City, KS; Tao Wang, University of Texas Southwestern Medical Center, Dallas, TX; Stephen R. Piccolo, Brigham Young University, Provo; University of Utah, Salt Lake City, Utah, UT; Roberto Vega, Russell Greiner, and Luke Kumar, University of Alberta; Alberta Innovates Centre for Machine Learning, Edmonton, Alberta, Canada; Christiane Fuchs, Helmholtz Zentrum München, Neuherberg; Technische Universität München, Garching, Germany; Eyal Gofer, The Hebrew University, Jerusalem, Israel; Russell D. Wolfinger, SAS Institute, Cary, NC; Kimberly Kanigel Winner and James C. Costello, University of Colorado, Anschutz Medical Campus, Aurora, CO; Chris Bare, Elias Chaibub Neto, Thomas Yu, Thea Norman, and Justin Guinney, Sage Bionetworks, Seattle, WA; Liji Shen and Fang Liz Zhou, Sanofi, Bridgewater, NJ; Kald Abdallah, AstraZeneca, Gaithersburg, MD; Gustavo Stolovitzky, IBM Research, Yorktown Heights; Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Howard R. Soule, Prostate Cancer Foundation, Santa Monica; Charles J. Ryan, University of California, San Francisco, CA; Christopher J. Sweeney, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Oliver Sartor, Tulane University, New Orleans, LA
| | - Charles J Ryan
- Fatemeh Seyednasrollah and Laura L. Elo, Turku Centre for Biotechnology; University of Turku; Åbo Akademi University, Turku, Finland; Devin C. Koestler, University of Kansas Medical Center, Kansas City, KS; Tao Wang, University of Texas Southwestern Medical Center, Dallas, TX; Stephen R. Piccolo, Brigham Young University, Provo; University of Utah, Salt Lake City, Utah, UT; Roberto Vega, Russell Greiner, and Luke Kumar, University of Alberta; Alberta Innovates Centre for Machine Learning, Edmonton, Alberta, Canada; Christiane Fuchs, Helmholtz Zentrum München, Neuherberg; Technische Universität München, Garching, Germany; Eyal Gofer, The Hebrew University, Jerusalem, Israel; Russell D. Wolfinger, SAS Institute, Cary, NC; Kimberly Kanigel Winner and James C. Costello, University of Colorado, Anschutz Medical Campus, Aurora, CO; Chris Bare, Elias Chaibub Neto, Thomas Yu, Thea Norman, and Justin Guinney, Sage Bionetworks, Seattle, WA; Liji Shen and Fang Liz Zhou, Sanofi, Bridgewater, NJ; Kald Abdallah, AstraZeneca, Gaithersburg, MD; Gustavo Stolovitzky, IBM Research, Yorktown Heights; Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Howard R. Soule, Prostate Cancer Foundation, Santa Monica; Charles J. Ryan, University of California, San Francisco, CA; Christopher J. Sweeney, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Oliver Sartor, Tulane University, New Orleans, LA
| | - Howard I Scher
- Fatemeh Seyednasrollah and Laura L. Elo, Turku Centre for Biotechnology; University of Turku; Åbo Akademi University, Turku, Finland; Devin C. Koestler, University of Kansas Medical Center, Kansas City, KS; Tao Wang, University of Texas Southwestern Medical Center, Dallas, TX; Stephen R. Piccolo, Brigham Young University, Provo; University of Utah, Salt Lake City, Utah, UT; Roberto Vega, Russell Greiner, and Luke Kumar, University of Alberta; Alberta Innovates Centre for Machine Learning, Edmonton, Alberta, Canada; Christiane Fuchs, Helmholtz Zentrum München, Neuherberg; Technische Universität München, Garching, Germany; Eyal Gofer, The Hebrew University, Jerusalem, Israel; Russell D. Wolfinger, SAS Institute, Cary, NC; Kimberly Kanigel Winner and James C. Costello, University of Colorado, Anschutz Medical Campus, Aurora, CO; Chris Bare, Elias Chaibub Neto, Thomas Yu, Thea Norman, and Justin Guinney, Sage Bionetworks, Seattle, WA; Liji Shen and Fang Liz Zhou, Sanofi, Bridgewater, NJ; Kald Abdallah, AstraZeneca, Gaithersburg, MD; Gustavo Stolovitzky, IBM Research, Yorktown Heights; Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Howard R. Soule, Prostate Cancer Foundation, Santa Monica; Charles J. Ryan, University of California, San Francisco, CA; Christopher J. Sweeney, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Oliver Sartor, Tulane University, New Orleans, LA
| | - Oliver Sartor
- Fatemeh Seyednasrollah and Laura L. Elo, Turku Centre for Biotechnology; University of Turku; Åbo Akademi University, Turku, Finland; Devin C. Koestler, University of Kansas Medical Center, Kansas City, KS; Tao Wang, University of Texas Southwestern Medical Center, Dallas, TX; Stephen R. Piccolo, Brigham Young University, Provo; University of Utah, Salt Lake City, Utah, UT; Roberto Vega, Russell Greiner, and Luke Kumar, University of Alberta; Alberta Innovates Centre for Machine Learning, Edmonton, Alberta, Canada; Christiane Fuchs, Helmholtz Zentrum München, Neuherberg; Technische Universität München, Garching, Germany; Eyal Gofer, The Hebrew University, Jerusalem, Israel; Russell D. Wolfinger, SAS Institute, Cary, NC; Kimberly Kanigel Winner and James C. Costello, University of Colorado, Anschutz Medical Campus, Aurora, CO; Chris Bare, Elias Chaibub Neto, Thomas Yu, Thea Norman, and Justin Guinney, Sage Bionetworks, Seattle, WA; Liji Shen and Fang Liz Zhou, Sanofi, Bridgewater, NJ; Kald Abdallah, AstraZeneca, Gaithersburg, MD; Gustavo Stolovitzky, IBM Research, Yorktown Heights; Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Howard R. Soule, Prostate Cancer Foundation, Santa Monica; Charles J. Ryan, University of California, San Francisco, CA; Christopher J. Sweeney, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Oliver Sartor, Tulane University, New Orleans, LA
| | - Laura L Elo
- Fatemeh Seyednasrollah and Laura L. Elo, Turku Centre for Biotechnology; University of Turku; Åbo Akademi University, Turku, Finland; Devin C. Koestler, University of Kansas Medical Center, Kansas City, KS; Tao Wang, University of Texas Southwestern Medical Center, Dallas, TX; Stephen R. Piccolo, Brigham Young University, Provo; University of Utah, Salt Lake City, Utah, UT; Roberto Vega, Russell Greiner, and Luke Kumar, University of Alberta; Alberta Innovates Centre for Machine Learning, Edmonton, Alberta, Canada; Christiane Fuchs, Helmholtz Zentrum München, Neuherberg; Technische Universität München, Garching, Germany; Eyal Gofer, The Hebrew University, Jerusalem, Israel; Russell D. Wolfinger, SAS Institute, Cary, NC; Kimberly Kanigel Winner and James C. Costello, University of Colorado, Anschutz Medical Campus, Aurora, CO; Chris Bare, Elias Chaibub Neto, Thomas Yu, Thea Norman, and Justin Guinney, Sage Bionetworks, Seattle, WA; Liji Shen and Fang Liz Zhou, Sanofi, Bridgewater, NJ; Kald Abdallah, AstraZeneca, Gaithersburg, MD; Gustavo Stolovitzky, IBM Research, Yorktown Heights; Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Howard R. Soule, Prostate Cancer Foundation, Santa Monica; Charles J. Ryan, University of California, San Francisco, CA; Christopher J. Sweeney, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Oliver Sartor, Tulane University, New Orleans, LA
| | - Fang Liz Zhou
- Fatemeh Seyednasrollah and Laura L. Elo, Turku Centre for Biotechnology; University of Turku; Åbo Akademi University, Turku, Finland; Devin C. Koestler, University of Kansas Medical Center, Kansas City, KS; Tao Wang, University of Texas Southwestern Medical Center, Dallas, TX; Stephen R. Piccolo, Brigham Young University, Provo; University of Utah, Salt Lake City, Utah, UT; Roberto Vega, Russell Greiner, and Luke Kumar, University of Alberta; Alberta Innovates Centre for Machine Learning, Edmonton, Alberta, Canada; Christiane Fuchs, Helmholtz Zentrum München, Neuherberg; Technische Universität München, Garching, Germany; Eyal Gofer, The Hebrew University, Jerusalem, Israel; Russell D. Wolfinger, SAS Institute, Cary, NC; Kimberly Kanigel Winner and James C. Costello, University of Colorado, Anschutz Medical Campus, Aurora, CO; Chris Bare, Elias Chaibub Neto, Thomas Yu, Thea Norman, and Justin Guinney, Sage Bionetworks, Seattle, WA; Liji Shen and Fang Liz Zhou, Sanofi, Bridgewater, NJ; Kald Abdallah, AstraZeneca, Gaithersburg, MD; Gustavo Stolovitzky, IBM Research, Yorktown Heights; Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Howard R. Soule, Prostate Cancer Foundation, Santa Monica; Charles J. Ryan, University of California, San Francisco, CA; Christopher J. Sweeney, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Oliver Sartor, Tulane University, New Orleans, LA
| | - Justin Guinney
- Fatemeh Seyednasrollah and Laura L. Elo, Turku Centre for Biotechnology; University of Turku; Åbo Akademi University, Turku, Finland; Devin C. Koestler, University of Kansas Medical Center, Kansas City, KS; Tao Wang, University of Texas Southwestern Medical Center, Dallas, TX; Stephen R. Piccolo, Brigham Young University, Provo; University of Utah, Salt Lake City, Utah, UT; Roberto Vega, Russell Greiner, and Luke Kumar, University of Alberta; Alberta Innovates Centre for Machine Learning, Edmonton, Alberta, Canada; Christiane Fuchs, Helmholtz Zentrum München, Neuherberg; Technische Universität München, Garching, Germany; Eyal Gofer, The Hebrew University, Jerusalem, Israel; Russell D. Wolfinger, SAS Institute, Cary, NC; Kimberly Kanigel Winner and James C. Costello, University of Colorado, Anschutz Medical Campus, Aurora, CO; Chris Bare, Elias Chaibub Neto, Thomas Yu, Thea Norman, and Justin Guinney, Sage Bionetworks, Seattle, WA; Liji Shen and Fang Liz Zhou, Sanofi, Bridgewater, NJ; Kald Abdallah, AstraZeneca, Gaithersburg, MD; Gustavo Stolovitzky, IBM Research, Yorktown Heights; Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Howard R. Soule, Prostate Cancer Foundation, Santa Monica; Charles J. Ryan, University of California, San Francisco, CA; Christopher J. Sweeney, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Oliver Sartor, Tulane University, New Orleans, LA
| | - James C Costello
- Fatemeh Seyednasrollah and Laura L. Elo, Turku Centre for Biotechnology; University of Turku; Åbo Akademi University, Turku, Finland; Devin C. Koestler, University of Kansas Medical Center, Kansas City, KS; Tao Wang, University of Texas Southwestern Medical Center, Dallas, TX; Stephen R. Piccolo, Brigham Young University, Provo; University of Utah, Salt Lake City, Utah, UT; Roberto Vega, Russell Greiner, and Luke Kumar, University of Alberta; Alberta Innovates Centre for Machine Learning, Edmonton, Alberta, Canada; Christiane Fuchs, Helmholtz Zentrum München, Neuherberg; Technische Universität München, Garching, Germany; Eyal Gofer, The Hebrew University, Jerusalem, Israel; Russell D. Wolfinger, SAS Institute, Cary, NC; Kimberly Kanigel Winner and James C. Costello, University of Colorado, Anschutz Medical Campus, Aurora, CO; Chris Bare, Elias Chaibub Neto, Thomas Yu, Thea Norman, and Justin Guinney, Sage Bionetworks, Seattle, WA; Liji Shen and Fang Liz Zhou, Sanofi, Bridgewater, NJ; Kald Abdallah, AstraZeneca, Gaithersburg, MD; Gustavo Stolovitzky, IBM Research, Yorktown Heights; Howard I. Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; Howard R. Soule, Prostate Cancer Foundation, Santa Monica; Charles J. Ryan, University of California, San Francisco, CA; Christopher J. Sweeney, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Oliver Sartor, Tulane University, New Orleans, LA
| | | |
Collapse
|
36
|
Mühleder S, Fuchs C, Basílio J, Szwarc D, Pill K, Labuda K, Slezak P, Siehs C, Pröll J, Priglinger E, Hoffmann C, Junger WG, Redl H, Holnthoner W. Purinergic P2Y 2 receptors modulate endothelial sprouting. Cell Mol Life Sci 2019; 77:885-901. [PMID: 31278420 DOI: 10.1007/s00018-019-03213-2] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2018] [Revised: 06/12/2019] [Accepted: 06/28/2019] [Indexed: 12/31/2022]
Abstract
Purinergic P2 receptors are critical regulators of several functions within the vascular system, including platelet aggregation, vascular inflammation, and vascular tone. However, a role for ATP release and P2Y receptor signalling in angiogenesis remains poorly defined. Here, we demonstrate that blood vessel growth is controlled by P2Y2 receptors. Endothelial sprouting and vascular tube formation were significantly dependent on P2Y2 expression and inhibition of P2Y2 using a selective antagonist blocked microvascular network generation. Mechanistically, overexpression of P2Y2 in endothelial cells induced the expression of the proangiogenic molecules CXCR4, CD34, and angiopoietin-2, while expression of VEGFR-2 was decreased. Interestingly, elevated P2Y2 expression caused constitutive phosphorylation of ERK1/2 and VEGFR-2. However, stimulation of cells with the P2Y2 agonist UTP did not influence sprouting unless P2Y2 was constitutively expressed. Finally, inhibition of VEGFR-2 impaired spontaneous vascular network formation induced by P2Y2 overexpression. Our data suggest that P2Y2 receptors have an essential function in angiogenesis, and that P2Y2 receptors present a therapeutic target to regulate blood vessel growth.
Collapse
Affiliation(s)
- Severin Mühleder
- Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, AUVA Research Center, Donaueschingenstrasse 13, 1200, Vienna, Austria
- Austrian Cluster for Tissue Regeneration, Vienna, Austria
- Kompetenzzentrum für MechanoBiologie (INTERREG V-A AT-CZ ATCZ133), Vienna, Austria
| | - Christiane Fuchs
- Austrian Cluster for Tissue Regeneration, Vienna, Austria
- Department Life Science Engineering, University of Applied Sciences Technikum Wien, Vienna, Austria
- Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, USA
| | - José Basílio
- Department of Vascular Biology and Thrombosis Research, Medical University of Vienna, Vienna, Austria
| | - Dorota Szwarc
- Austrian Cluster for Tissue Regeneration, Vienna, Austria
- Department Life Science Engineering, University of Applied Sciences Technikum Wien, Vienna, Austria
| | - Karoline Pill
- Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, AUVA Research Center, Donaueschingenstrasse 13, 1200, Vienna, Austria
- Austrian Cluster for Tissue Regeneration, Vienna, Austria
| | - Krystyna Labuda
- Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, AUVA Research Center, Donaueschingenstrasse 13, 1200, Vienna, Austria
- Austrian Cluster for Tissue Regeneration, Vienna, Austria
| | - Paul Slezak
- Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, AUVA Research Center, Donaueschingenstrasse 13, 1200, Vienna, Austria
- Austrian Cluster for Tissue Regeneration, Vienna, Austria
| | - Christian Siehs
- Mag. Dipl.-Ing. Dr. Christian Siehs, IT-Services, GLN 9110002040261, Vienna, Austria
| | - Johannes Pröll
- Austrian Cluster for Tissue Regeneration, Vienna, Austria
- Center for Medical Research, Johannes Kepler University, Linz, Austria
- Red Cross Blood Transfusion Service, Linz, Austria
| | - Eleni Priglinger
- Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, AUVA Research Center, Donaueschingenstrasse 13, 1200, Vienna, Austria
- Austrian Cluster for Tissue Regeneration, Vienna, Austria
| | - Carsten Hoffmann
- Institut für Molekulare Zellbiologie, CMB-Center for Molecular Biomedicine, Universitätsklinikum Jena, Friedrich-Schiller-Universität, Jena, Germany
| | - Wolfgang G Junger
- Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, AUVA Research Center, Donaueschingenstrasse 13, 1200, Vienna, Austria
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, 02215, MA, USA
| | - Heinz Redl
- Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, AUVA Research Center, Donaueschingenstrasse 13, 1200, Vienna, Austria
- Austrian Cluster for Tissue Regeneration, Vienna, Austria
| | - Wolfgang Holnthoner
- Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, AUVA Research Center, Donaueschingenstrasse 13, 1200, Vienna, Austria.
- Austrian Cluster for Tissue Regeneration, Vienna, Austria.
| |
Collapse
|
37
|
Chau I, Bendell J, Soriano A, Arkenau H, Cultrera J, Santana-Davila R, Calvo E, Tourneau CL, Zender L, Mi G, Schelman W, Ferry D, Herbst R, Fuchs C. Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz157.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Tabernero J, Van Cutsem E, Bang Y, Fuchs C, Wyrwicz L, Lee K, Kudaba I, Garrido M, Chung H, Castro Salguero H, Mansoor W, Braghiroli M, Goekkurt E, Chao J, Wainberg Z, Kher U, Shah S, Kang S, Shitara K. Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz183.001] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
39
|
Chung H, Bang Y, Fuchs C, Qin S, Satoh T, Shitara K, Tabernero J, Van Cutsem E, Cao Z, Chen X, Kang S, Shih C, Janjigian Y. KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer: a double-blind, randomized, placebo-controlled phase 3 study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.093] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Krautenbacher N, Flach N, Böck A, Laubhahn K, Laimighofer M, Theis FJ, Ankerst DP, Fuchs C, Schaub B. A strategy for high-dimensional multivariable analysis classifies childhood asthma phenotypes from genetic, immunological, and environmental factors. Allergy 2019; 74:1364-1373. [PMID: 30737985 PMCID: PMC6767756 DOI: 10.1111/all.13745] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2018] [Revised: 12/22/2018] [Accepted: 01/06/2019] [Indexed: 12/14/2022]
Abstract
Background Associations between childhood asthma phenotypes and genetic, immunological, and environmental factors have been previously established. Yet, strategies to integrate high‐dimensional risk factors from multiple distinct data sets, and thereby increase the statistical power of analyses, have been hampered by a preponderance of missing data and lack of methods to accommodate them. Methods We assembled questionnaire, diagnostic, genotype, microarray, RT‐qPCR, flow cytometry, and cytokine data (referred to as data modalities) to use as input factors for a classifier that could distinguish healthy children, mild‐to‐moderate allergic asthmatics, and nonallergic asthmatics. Based on data from 260 German children aged 4‐14 from our university outpatient clinic, we built a novel multilevel prediction approach for asthma outcome which could deal with a present complex missing data structure. Results The optimal learning method was boosting based on all data sets, achieving an area underneath the receiver operating characteristic curve (AUC) for three classes of phenotypes of 0.81 (95%‐confidence interval (CI): 0.65‐0.94) using leave‐one‐out cross‐validation. Besides improving the AUC, our integrative multilevel learning approach led to tighter CIs than using smaller complete predictor data sets (AUC = 0.82 [0.66‐0.94] for boosting). The most important variables for classifying childhood asthma phenotypes comprised novel identified genes, namely PKN2 (protein kinase N2), PTK2 (protein tyrosine kinase 2), and ALPP (alkaline phosphatase, placental). Conclusion Our combination of several data modalities using a novel strategy improved classification of childhood asthma phenotypes but requires validation in external populations. The generic approach is applicable to other multilevel data‐based risk prediction settings, which typically suffer from incomplete data.
Collapse
Affiliation(s)
- Norbert Krautenbacher
- Institute of Computational Biology Helmholtz Zentrum München German Research Center for Environmental Health GmbH Neuherberg Germany
- Technische Universität München Center for Mathematics Chair of Mathematical Modeling of Biological Systems Garching Germany
| | - Nicolai Flach
- Institute of Computational Biology Helmholtz Zentrum München German Research Center for Environmental Health GmbH Neuherberg Germany
- Technische Universität München Center for Mathematics Chair of Mathematical Modeling of Biological Systems Garching Germany
| | - Andreas Böck
- Department of Pulmonary and Allergy Dr. von Hauner Children's Hospital LMU Munich Germany
| | - Kristina Laubhahn
- Department of Pulmonary and Allergy Dr. von Hauner Children's Hospital LMU Munich Germany
- Member of German Lung Centre (DZL) CPC Munich Germany
| | - Michael Laimighofer
- Institute of Computational Biology Helmholtz Zentrum München German Research Center for Environmental Health GmbH Neuherberg Germany
- Technische Universität München Center for Mathematics Chair of Mathematical Modeling of Biological Systems Garching Germany
| | - Fabian J. Theis
- Institute of Computational Biology Helmholtz Zentrum München German Research Center for Environmental Health GmbH Neuherberg Germany
- Technische Universität München Center for Mathematics Chair of Mathematical Modeling of Biological Systems Garching Germany
| | - Donna P. Ankerst
- Technische Universität München Center for Mathematics Chair of Mathematical Modeling of Biological Systems Garching Germany
- University of Texas Health Science Center at San Antonio San Antonio Texas
| | - Christiane Fuchs
- Institute of Computational Biology Helmholtz Zentrum München German Research Center for Environmental Health GmbH Neuherberg Germany
- Technische Universität München Center for Mathematics Chair of Mathematical Modeling of Biological Systems Garching Germany
- Faculty of Business Administration and Economics Bielefeld University Bielefeld Germany
| | - Bianca Schaub
- Department of Pulmonary and Allergy Dr. von Hauner Children's Hospital LMU Munich Germany
- Member of German Lung Centre (DZL) CPC Munich Germany
| |
Collapse
|
41
|
Junge S, Reimpell P, Hellmuth T, Fuchs C. P201 Adherence in nebulisation therapy of paediatric patients with cystic fibrosis. J Cyst Fibros 2019. [DOI: 10.1016/s1569-1993(19)30495-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
42
|
Fuchs C, Wang Y, Farinelli W, Anderson R, Tam J. 954 MagneTEskin – Orientation matters. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.1030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
43
|
Affiliation(s)
- Mohamed El Omari
- Department of Applied Mathematics, Faculty of Sciences and Techniques, Sultan Moulay Slimane University, Béni-Mellal, Morocco
| | - Hamid El Maroufy
- Department of Applied Mathematics, Faculty of Sciences and Techniques, Sultan Moulay Slimane University, Béni-Mellal, Morocco
| | - Christiane Fuchs
- Bielefeld University, Faculty of Business Administration and Economics, Bielefeld, Germany
- Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Institute of Computational Biology, Neuherberg, Germany
- Center for Mathematics, Chair of Mathematical Modeling of Biological Systems, Technische Universität München, Garching, Germany
| |
Collapse
|
44
|
Fuchs C, Wauschkuhn S, Scheer C, Vollmer M, Meissner K, Kuhn SO, Hahnenkamp K, Morelli A, Gründling M, Rehberg S. Continuing chronic beta-blockade in the acute phase of severe sepsis and septic shock is associated with decreased mortality rates up to 90 days. Br J Anaesth 2019; 119:616-625. [PMID: 29121280 DOI: 10.1093/bja/aex231] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/21/2017] [Indexed: 12/24/2022] Open
Abstract
Background There is growing evidence that beta-blockade may reduce mortality in selected patients with sepsis. However, it is unclear if a pre-existing, chronic oral beta-blocker therapy should be continued or discontinued during the acute phase of severe sepsis and septic shock. Methods The present secondary analysis of a prospective observational single centre trial compared patient and treatment characteristics, length of stay and mortality rates between adult patients with severe sepsis or septic shock, in whom chronic beta-blocker therapy was continued or discontinued, respectively. The acute phase was defined as the period ranging from two days before to three days after disease onset. Multivariable Cox regression analysis was performed to compare survival outcomes in patients with pre-existing chronic beta-blockade. Results A total of 296 patients with severe sepsis or septic shock and pre-existing, chronic oral beta-blocker therapy were included. Chronic beta-blocker medication was discontinued during the acute phase of sepsis in 129 patients and continued in 167 patients. Continuation of beta-blocker therapy was significantly associated with decreased hospital (P=0.03), 28-day (P=0.04) and 90-day mortality rates (40.7% vs 52.7%; P=0.046) in contrast to beta-blocker cessation. The differences in survival functions were validated by a Log-rank test (P=0.01). Multivariable analysis identified the continuation of chronic beta-blocker therapy as an independent predictor of improved survival rates (HR = 0.67, 95%-CI (0.48, 0.95), P=0.03). Conclusions Continuing pre-existing chronic beta-blockade might be associated with decreased mortality rates up to 90 days in septic patients.
Collapse
Affiliation(s)
- C Fuchs
- Department of Anaesthesiology, University Hospital of Greifswald, Ferdinand-Sauerbruch-Strasse, 17475 Greifswald, Germany
| | - S Wauschkuhn
- Department of Anaesthesiology, University Hospital of Greifswald, Ferdinand-Sauerbruch-Strasse, 17475 Greifswald, Germany
| | - C Scheer
- Department of Anaesthesiology, University Hospital of Greifswald, Ferdinand-Sauerbruch-Strasse, 17475 Greifswald, Germany
| | - M Vollmer
- Institute of Bioinformatics, University Hospital of Greifswald, Greifswald, Germany
| | - K Meissner
- Department of Anaesthesiology, University Hospital of Greifswald, Ferdinand-Sauerbruch-Strasse, 17475 Greifswald, Germany
| | - S-O Kuhn
- Department of Anaesthesiology, University Hospital of Greifswald, Ferdinand-Sauerbruch-Strasse, 17475 Greifswald, Germany
| | - K Hahnenkamp
- Department of Anaesthesiology, University Hospital of Greifswald, Ferdinand-Sauerbruch-Strasse, 17475 Greifswald, Germany
| | - A Morelli
- Department of Cardiovascular, Respiratory, Nephrological, Anesthesiological and Geriatric Sciences, University of Rome, La Sapienza, Rome, Italy
| | - M Gründling
- Department of Anaesthesiology, University Hospital of Greifswald, Ferdinand-Sauerbruch-Strasse, 17475 Greifswald, Germany
| | - S Rehberg
- Department of Anaesthesiology, University Hospital of Greifswald, Ferdinand-Sauerbruch-Strasse, 17475 Greifswald, Germany
| |
Collapse
|
45
|
Fuchs C, Brüggemann A, Weseloh MJ, Berger C, Möller C, Reinhard S, Hader J, Moloney JV, Bäumner A, Koch SW, Stolz W. Author Correction: High-temperature operation of electrical injection type-II (GaIn)As/Ga(AsSb)/(GaIn)As “W”-quantum well lasers emitting at 1.3 µm. Sci Rep 2018; 8:7891. [PMID: 29760512 PMCID: PMC5951860 DOI: 10.1038/s41598-018-25808-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
46
|
Dirmeier S, Fuchs C, Mueller NS, Theis FJ. netReg: network-regularized linear models for biological association studies. Bioinformatics 2018; 34:896-898. [PMID: 29077797 PMCID: PMC6030897 DOI: 10.1093/bioinformatics/btx677] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2017] [Accepted: 10/24/2017] [Indexed: 11/26/2022] Open
Abstract
Summary Modelling biological associations or dependencies using linear regression is often complicated when the analyzed data-sets are high-dimensional and less observations than variables are available (n ≪ p). For genomic data-sets penalized regression methods have been applied settling this issue. Recently proposed regression models utilize prior knowledge on dependencies, e.g. in the form of graphs, arguing that this information will lead to more reliable estimates for regression coefficients. However, none of the proposed models for multivariate genomic response variables have been implemented as a computationally efficient, freely available library. In this paper we propose netReg, a package for graph-penalized regression models that use large networks and thousands of variables. netReg incorporates a priori generated biological graph information into linear models yielding sparse or smooth solutions for regression coefficients. Availability and implementation netReg is implemented as both R-package and C ++ commandline tool. The main computations are done in C ++, where we use Armadillo for fast matrix calculations and Dlib for optimization. The R package is freely available on Bioconductorhttps://bioconductor.org/packages/netReg. The command line tool can be installed using the conda channel Bioconda. Installation details, issue reports, development versions, documentation and tutorials for the R and C ++ versions and the R package vignette can be found on GitHub https://dirmeier.github.io/netReg/. The GitHub page also contains code for benchmarking and example datasets used in this paper.
Collapse
Affiliation(s)
- Simon Dirmeier
- Department of Biosystems Science and Engineering, ETH Zurich, 4058 Basel, Switzerland
| | - Christiane Fuchs
- Institute of Computational Biology, Helmholtz Zentrum München, 85764 Neuherberg, Germany.,Department of Mathematics, Technische Universität München, 85748 Garching, Germany
| | - Nikola S Mueller
- Institute of Computational Biology, Helmholtz Zentrum München, 85764 Neuherberg, Germany
| | - Fabian J Theis
- Institute of Computational Biology, Helmholtz Zentrum München, 85764 Neuherberg, Germany.,Department of Mathematics, Technische Universität München, 85748 Garching, Germany
| |
Collapse
|
47
|
Neschen S, Wu M, Fuchs C, Kondofersky I, Theis FJ, de Angelis MH, Häring HU, Sartorius T. Impact of Brain Fatty Acid Signaling on Peripheral Insulin Action in Mice. Exp Clin Endocrinol Diabetes 2018; 128:20-29. [PMID: 30396212 DOI: 10.1055/a-0735-9533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
AIMS AND METHODS Glucose homeostasis and energy balance are under control by peripheral and brain processes. Especially insulin signaling in the brain seems to impact whole body glucose homeostasis and interacts with fatty acid signaling. In humans circulating saturated fatty acids are negatively associated with brain insulin action while animal studies suggest both positive and negative interactions of fatty acids and insulin brain action. This apparent discrepancy might reflect a difference between acute and chronic fatty acid signaling. To address this question we investigated the acute effect of an intracerebroventricular palmitic acid administration on peripheral glucose homeostasis. We developed and implemented a method for simultaneous monitoring of brain activity and peripheral insulin action in freely moving mice by combining radiotelemetry electrocorticography (ECoG) and euglycemic-hyperinsulinemic clamps. This method allowed gaining insight in the early kinetics of brain fatty acid signaling and its contemporaneous effect on liver function in vivo, which, to our knowledge, has not been assessed so far in mice. RESULTS Insulin-induced brain activity in the theta and beta band was decreased by acute intracerebroventricular application of palmitic acid. Peripherally it amplified insulin action as demonstrated by a significant inhibition of endogenous glucose production and increased glucose infusion rate. Moreover, our results further revealed that the brain effect of peripheral insulin is modulated by palmitic acid load in the brain. CONCLUSION These findings suggest that insulin action is amplified in the periphery and attenuated in the brain by acute palmitic acid application. Thus, our results indicate that acute palmitic acid signaling in the brain may be different from chronic effects.
Collapse
Affiliation(s)
- Susanne Neschen
- Institute of Experimental Genetics, German Mouse Clinic, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany.,German Center for Diabetes Research (DZD), Neuherberg, Germany
| | - Moya Wu
- Institute of Experimental Genetics, German Mouse Clinic, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany.,German Center for Diabetes Research (DZD), Neuherberg, Germany
| | - Christiane Fuchs
- Institute of Computational Biology, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany.,Center for Mathematics, Chair of Mathematical Modeling of Biological Systems, Technical University of Munich, Garching, Germany
| | - Ivan Kondofersky
- Institute of Computational Biology, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany.,Center for Mathematics, Chair of Mathematical Modeling of Biological Systems, Technical University of Munich, Garching, Germany
| | - Fabian J Theis
- Institute of Computational Biology, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany.,Center for Mathematics, Chair of Mathematical Modeling of Biological Systems, Technical University of Munich, Garching, Germany
| | - Martin Hrabě de Angelis
- Institute of Experimental Genetics, German Mouse Clinic, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany.,German Center for Diabetes Research (DZD), Neuherberg, Germany
| | - Hans-Ulrich Häring
- German Center for Diabetes Research (DZD), Neuherberg, Germany.,Department of Internal Medicine, Division of Endocrinology, Diabetology, Vascular Disease, Nephrology and Clinical Chemistry, University of Tuebingen, Tuebingen, Germany.,Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tuebingen (IDM), Tuebingen, Germany
| | - Tina Sartorius
- German Center for Diabetes Research (DZD), Neuherberg, Germany.,Department of Internal Medicine, Division of Endocrinology, Diabetology, Vascular Disease, Nephrology and Clinical Chemistry, University of Tuebingen, Tuebingen, Germany.,Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center Munich at the University of Tuebingen (IDM), Tuebingen, Germany
| |
Collapse
|
48
|
Fuchs HF, Müller DT, Berlth F, Maus MK, Fuchs C, Dübbers M, Schröder W, Bruns CJ, Leers JM. Simultaneous laryngopharyngeal pH monitoring (Restech) and conventional esophageal pH monitoring-correlation using a large patient cohort of more than 100 patients with suspected gastroesophageal reflux disease. Dis Esophagus 2018. [PMID: 29534167 DOI: 10.1093/dote/doy018] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
24-hour esophageal pH-metry is not designed to detect laryngopharyngeal reflux (LPR). The new laryngopharyngeal pH-monitoring system (Restech) may detect LPR better. There is no established correlation between these two techniques as only small case series exist. The aim of this study is to examine the correlation between the two techniques with a large patient cohort. All patients received a complete diagnostic workup for gastroesophageal reflux including symptom evaluation, endoscopy, 24-hour pH-metry, high resolution manometry, and Restech. Consecutive patients with suspected gastroesophageal reflux and disease-related extra-esophageal symptoms were evaluated using 24-hour laryngopharyngeal and concomitant esophageal pH-monitoring. Subsequently, the relationship between the two techniques was evaluated subdividing the different reflux scenarios into four groups. A total of 101 patients from December 2013 to February 2017 were included. All patients presented extra-esophageal symptoms such as cough, hoarseness, asthma symptoms, and globus sensation. Classical reflux symptoms such as heartburn (71%), regurgitation (60%), retrosternal pain (54%), and dysphagia (32%) were also present. Esophageal 24-hour pH-metry was positive in 66 patients (65%) with a mean DeMeester Score of 66.7 [15-292]. Four different reflux scenarios were detected (group A-D): in 39% of patients with abnormal esophageal pH-metry, Restech evaluation was normal (group A, n = 26, mean DeMeester-score = 57.9 [15-255], mean Ryan score = 2.6 [2-8]). In 23% of patients with normal pH-metry (n = 8, group B), Restech evaluation was abnormal (mean DeMeester-score 10.5 [5-13], mean Ryan score 63.5 [27-84]). The remaining groups C and D showed corresponding results. Restech evaluation was positive in 48% of cases in this highly selective patient cohort. As demonstrated by four reflux scenarios, esophageal pH-metry and Restech do not necessarily need to correspond. Especially in patients with borderline abnormal 24-hour pH-metry, Restech may help to support the decision for or against laparoscopic anti-reflux surgery.
Collapse
Affiliation(s)
- H F Fuchs
- Department of General, Visceral and Cancer Surgery, University of Cologne, Cologne, Germany
| | - D T Müller
- Department of General, Visceral and Cancer Surgery, University of Cologne, Cologne, Germany
| | - F Berlth
- Department of General, Visceral and Cancer Surgery, University of Cologne, Cologne, Germany
| | - M K Maus
- Department of General, Visceral and Cancer Surgery, University of Cologne, Cologne, Germany
| | - C Fuchs
- Department of General, Visceral and Cancer Surgery, University of Cologne, Cologne, Germany
| | - M Dübbers
- Department of General, Visceral and Cancer Surgery, University of Cologne, Cologne, Germany
| | - W Schröder
- Department of General, Visceral and Cancer Surgery, University of Cologne, Cologne, Germany
| | - C J Bruns
- Department of General, Visceral and Cancer Surgery, University of Cologne, Cologne, Germany
| | - J M Leers
- Department of General, Visceral and Cancer Surgery, University of Cologne, Cologne, Germany
| |
Collapse
|
49
|
Wille K, Sadjadian P, Becker T, Kolatzki V, Horstmann A, Fuchs C, Griesshammer M. High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation. Ann Hematol 2018; 98:93-100. [PMID: 30155552 DOI: 10.1007/s00277-018-3483-6] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2018] [Accepted: 08/20/2018] [Indexed: 12/30/2022]
Abstract
Venous thromboembolism (VTE) is a major burden in patients with BCR-ABL-negative myeloproliferative neoplasms (MPN). In addition to cytoreductive treatment anticoagulation is mandatory, but optimal duration of anticoagulation is a matter of debate. In our single center study, we retrospectively included 526 MPN patients. In total, 78 of 526 MPN patients (14.8%) had 99 MPN-associated VTE. Median age at first VTE was 52.5 years (range 23-81). During a study period of 3497 years, a VTE event rate of 1.7% per patient/year was detected. 38.4% (38/99) of all VTEs appeared before or at MPN diagnosis and 55.6% (55/99) occurred at "uncommon" sites like splanchnic or cerebral veins. MPN patients with VTEs were significantly more female (p = 0.028), JAK2 positive (p = 0.018), or had a polycythemia vera (p = 0.009). MPN patients without VTEs were more often CALR positive (p = 0.023). Total study period after first VTE was 336 years with 20 VTE recurrences accounting for a recurrence rate of 6% per patient/year. In 36 of 71 MPN patients with anticoagulation therapy after first VTE event (50.7%), prophylactic anticoagulation was terminated after a median time of 6 months (range 1-61); 13 of those 36 patients (36.1%) had a VTE recurrence after a median of 13 months (range 4-168). In contrast, only three of 35 (8.6%) patients with ongoing anticoagulation had a VTE recurrence (p = 0.0127). Thus, termination of prophylactic anticoagulation was associated with a significantly higher risk of VTE recurrence. Our data suggest that in MPN patients with VTE, a prolonged duration of anticoagulation may be beneficial.
Collapse
Affiliation(s)
- Kai Wille
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Hans-Nolte-Straße 1, 32429, Minden, Germany.
| | - Parvis Sadjadian
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Hans-Nolte-Straße 1, 32429, Minden, Germany
| | - Tatjana Becker
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Hans-Nolte-Straße 1, 32429, Minden, Germany
| | - Vera Kolatzki
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Hans-Nolte-Straße 1, 32429, Minden, Germany
| | - Anette Horstmann
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Hans-Nolte-Straße 1, 32429, Minden, Germany
| | - Christiane Fuchs
- Faculty of Business Administration and Economics, Bielefeld University, Universitätsstraße 25, 33615, Bielefeld, Germany.,Institute of Computational Biology, Helmholtz Zentrum München, German Research Center for Environmental Health GmbH, Ingolstädter Landstr. 1, 85764, Neuherberg, Germany
| | - Martin Griesshammer
- University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center Minden, University of Bochum, Hans-Nolte-Straße 1, 32429, Minden, Germany
| |
Collapse
|
50
|
Maleiner B, Tomasch J, Heher P, Spadiut O, Rünzler D, Fuchs C. The Importance of Biophysical and Biochemical Stimuli in Dynamic Skeletal Muscle Models. Front Physiol 2018; 9:1130. [PMID: 30246791 PMCID: PMC6113794 DOI: 10.3389/fphys.2018.01130] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2017] [Accepted: 07/30/2018] [Indexed: 12/31/2022] Open
Abstract
Classical approaches to engineer skeletal muscle tissue based on current regenerative and surgical procedures still do not meet the desired outcome for patient applications. Besides the evident need to create functional skeletal muscle tissue for the repair of volumetric muscle defects, there is also growing demand for platforms to study muscle-related diseases, such as muscular dystrophies or sarcopenia. Currently, numerous studies exist that have employed a variety of biomaterials, cell types and strategies for maturation of skeletal muscle tissue in 2D and 3D environments. However, researchers are just at the beginning of understanding the impact of different culture settings and their biochemical (growth factors and chemical changes) and biophysical cues (mechanical properties) on myogenesis. With this review we intend to emphasize the need for new in vitro skeletal muscle (disease) models to better recapitulate important structural and functional aspects of muscle development. We highlight the importance of choosing appropriate system components, e.g., cell and biomaterial type, structural and mechanical matrix properties or culture format, and how understanding their interplay will enable researchers to create optimized platforms to investigate myogenesis in healthy and diseased tissue. Thus, we aim to deliver guidelines for experimental designs to allow estimation of the potential influence of the selected skeletal muscle tissue engineering setup on the myogenic outcome prior to their implementation. Moreover, we offer a workflow to facilitate identifying and selecting different analytical tools to demonstrate the successful creation of functional skeletal muscle tissue. Ultimately, a refinement of existing strategies will lead to further progression in understanding important aspects of muscle diseases, muscle aging and muscle regeneration to improve quality of life of patients and enable the establishment of new treatment options.
Collapse
Affiliation(s)
- Babette Maleiner
- Department of Biochemical Engineering, University of Applied Sciences Technikum Wien, Vienna, Austria.,The Austrian Cluster for Tissue Regeneration, Vienna, Austria
| | - Janine Tomasch
- Department of Biochemical Engineering, University of Applied Sciences Technikum Wien, Vienna, Austria.,The Austrian Cluster for Tissue Regeneration, Vienna, Austria
| | - Philipp Heher
- The Austrian Cluster for Tissue Regeneration, Vienna, Austria.,Ludwig Boltzmann Institute for Experimental and Clinical Traumatology/AUVA Research Center, Vienna, Austria.,Trauma Care Consult GmbH, Vienna, Austria
| | - Oliver Spadiut
- Institute of Chemical Engineering, Vienna University of Technology, Vienna, Austria
| | - Dominik Rünzler
- Department of Biochemical Engineering, University of Applied Sciences Technikum Wien, Vienna, Austria.,The Austrian Cluster for Tissue Regeneration, Vienna, Austria
| | - Christiane Fuchs
- Department of Biochemical Engineering, University of Applied Sciences Technikum Wien, Vienna, Austria.,The Austrian Cluster for Tissue Regeneration, Vienna, Austria
| |
Collapse
|